# Electronic Version v1.1 Stylesheet Version v1.1

 SUBMISSION TYPE:
 NEW ASSIGNMENT

 NATURE OF CONVEYANCE:
 SECURITY INTEREST

#### **CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type		
N.V. PERRICONE LLC		103/03/2006 1	LIMITED LIABILITY COMPANY: DELAWARE		

#### **RECEIVING PARTY DATA**

Name:	UNION BANK OF CALIFORNIA, N.A., as Agent for the Lenders
Street Address:	445 SOUTH FIGUEROA STREET, 13th FLOOR
Internal Address:	ATTN: CHRISTOPHER FREEMAN
City:	LOS ANGELES
State/Country:	CALIFORNIA
Postal Code:	90071
Entity Type:	NATIONAL BANKING ASSOCIATION:

#### PROPERTY NUMBERS Total: 42

Property Type	Number	Word Mark
Registration Number:	2315317	NTP COMPLEX
Registration Number:	2237822	N.V. PERRICONE, M.D. COSMECEUTICALS
Registration Number:	2920772	N.V. PERRICONE, M.D. COSMECEUTICALS
Registration Number:	2640234	THE WRINKLE CURE
Registration Number:	2832268	THE WRINKLE CURE
Registration Number:	2674550	N.V. PERRICONE, M.D. NUTRICEUTICALS
Registration Number:	2765243	OUTPATIENT THERAPY
Registration Number:	2952811	THE PERRICONE PRESCRIPTION
Registration Number:	2935651	SKIN & TOTAL BODY
Registration Number:	2993474	NEUROPEPTIDE FACIAL SERUM PREP
Serial Number:	78799850	N.V. PERRICONE, M.D.
Serial Number:	78652196	THE WRINKLE CURE DIET
Serial Number:	78488493	THE WRINKLE CURE

TRADEMARK REEL: 003259 FRAME: 0506

900043551

Serial Number:	78731279	THE WRINKLE CURE CLINIC
Serial Number:	78652234	LAYERED REJUVENATION TECHNOLOGY
Serial Number:	76409298	THE PERRICONE PRESCRIPTION
Serial Number:	78486124	THE PERRICONE PRESCRIPTION
Serial Number:	78486014	THE PERRICONE PROMISE
Serial Number:	78496884	THE BRAIN-BEAUTY CONNECTION
Serial Number:	76460820	N.V. PERRICONE, M.D. THERAPEUTICS
Serial Number:	78341291	N.V. PERRICONE, M.D. THERAPEUTICS
Serial Number:	78690438	N.V. PERRICONE, M.D. THERAPEUTICS
Serial Number:	78213497	ELECTRIC-STIM
Serial Number:	78214351	ELECTRIC-STIM GLOVE
Serial Number:	78355532	NEUROPEPTIDE FACIAL CONFORMER
Serial Number:	78499773	NEUROPEPTIDE EYE AREA CONTOUR
Serial Number:	78496958	THE THREE-DAY NUTRITIONAL FACE -LIFT
Serial Number:	78526255	FACE FIRMING ACTIVATOR
Serial Number:	78601148	NEUROPEPTIDE FACIAL CONTOUR
Serial Number:	78711979	N.V. PERRICONE M.D. MEN'S SKIN FITNESS
Serial Number:	78727233	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS
Serial Number:	78785748	MOIST LIPS
Serial Number:	78785784	NUTRIENT FACE FORTIFIER
Serial Number:	78785800	BODY HYDRATOR
Serial Number:	78785816	FACE HYDRATOR
Serial Number:	78785824	HYDRATING NUTRIENT MASK
Serial Number:	78799773	THE PERRICONE WEIGHT-LOSS DIET
Serial Number:	78799785	DR. PERRICONE'S SKIN AND TOTAL BODY NUTRITIONAL SUPPLEMENTS
Serial Number:	78305861	N.V. PERRICONE, M.D., PHARMACEUTICALS
Serial Number:	78341309	N.V. PERRICONE, M.D. PHARMACEUTICALS
Serial Number:	78701367	N.V. PERRICONE M.D. MEN'S FITNESS
Serial Number:	78785714	GENTLE CLEANSER

#### **CORRESPONDENCE DATA**

Fax Number: (213)629-1033

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (213) 488-7100

Email: kevin.davis@pillsburylaw.com

Correspondent Name: WANSUN SONG, ESQ.

Address Line 1: 725 SOUTH FIGUEROA STREET, SUITE 2800
Address Line 2: PILLSBURY WINTHROP SHAW PITTMAN LLP
Address Line 4: LOS ANGELES, CALIFORNIA 90017-5406

ATTORNEY DOCKET NUMBER:	005550-0000316
NAME OF SUBMITTER:	WANSUN SONG
Signature:	/Wansun Song/
Date:	03/06/2006

**Total Attachments: 66** 

source=SECURITY AGREEMENT-TM#page1.tif source=SECURITY AGREEMENT-TM#page2.tif source=SECURITY AGREEMENT-TM#page3.tif source=SECURITY AGREEMENT-TM#page4.tif source=SECURITY AGREEMENT-TM#page5.tif source=SECURITY AGREEMENT-TM#page6.tif source=SECURITY AGREEMENT-TM#page7.tif source=SECURITY AGREEMENT-TM#page8.tif source=SECURITY AGREEMENT-TM#page9.tif source=SECURITY AGREEMENT-TM#page10.tif source=SECURITY AGREEMENT-TM#page11.tif source=SECURITY AGREEMENT-TM#page12.tif source=SECURITY AGREEMENT-TM#page13.tif source=SECURITY AGREEMENT-TM#page14.tif source=SECURITY AGREEMENT-TM#page15.tif source=SECURITY AGREEMENT-TM#page16.tif source=SECURITY AGREEMENT-TM#page17.tif source=SECURITY AGREEMENT-TM#page18.tif source=SECURITY AGREEMENT-TM#page19.tif source=SECURITY AGREEMENT-TM#page20.tif source=SECURITY AGREEMENT-TM#page21.tif source=SECURITY AGREEMENT-TM#page22.tif source=SECURITY AGREEMENT-TM#page23.tif source=SECURITY AGREEMENT-TM#page24.tif source=SECURITY AGREEMENT-TM#page25.tif source=SECURITY AGREEMENT-TM#page26.tif source=SECURITY AGREEMENT-TM#page27.tif source=SECURITY AGREEMENT-TM#page28.tif source=SECURITY AGREEMENT-TM#page29.tif source=SECURITY AGREEMENT-TM#page30.tif source=SECURITY AGREEMENT-TM#page31.tif source=SECURITY AGREEMENT-TM#page32.tif source=SECURITY AGREEMENT-TM#page33.tif source=SECURITY AGREEMENT-TM#page34.tif source=SECURITY AGREEMENT-TM#page35.tif source=SECURITY AGREEMENT-TM#page36.tif source=SECURITY AGREEMENT-TM#page37.tif source=SECURITY AGREEMENT-TM#page38.tif source=SECURITY AGREEMENT-TM#page39.tif

source=SECURITY AGREEMENT-TM#page40.tif source=SECURITY AGREEMENT-TM#page41.tif source=SECURITY AGREEMENT-TM#page42.tif source=SECURITY AGREEMENT-TM#page43.tif source=SECURITY AGREEMENT-TM#page44.tif source=SECURITY AGREEMENT-TM#page45.tif source=SECURITY AGREEMENT-TM#page46.tif source=SECURITY AGREEMENT-TM#page47.tif source=SECURITY AGREEMENT-TM#page48.tif source=SECURITY AGREEMENT-TM#page49.tif source=SECURITY AGREEMENT-TM#page50.tif source=SECURITY AGREEMENT-TM#page51.tif source=SECURITY AGREEMENT-TM#page52.tif source=SECURITY AGREEMENT-TM#page53.tif source=SECURITY AGREEMENT-TM#page54.tif source=SECURITY AGREEMENT-TM#page55.tif source=SECURITY AGREEMENT-TM#page56.tif source=SECURITY AGREEMENT-TM#page57.tif source=SECURITY AGREEMENT-TM#page58.tif source=SECURITY AGREEMENT-TM#page59.tif source=SECURITY AGREEMENT-TM#page60.tif source=SECURITY AGREEMENT-TM#page61.tif source=SECURITY AGREEMENT-TM#page62.tif source=SECURITY AGREEMENT-TM#page63.tif source=SECURITY AGREEMENT-TM#page64.tif source=SECURITY AGREEMENT-TM#page65.tif source=SECURITY AGREEMENT-TM#page66.tif

### **SECURITY AGREEMENT**

This SECURITY AGREEMENT is dated as of March 3, 2006, and made by N.V. PERRICONE LLC, a Delaware limited liability company (the "<u>Grantor</u>"), in favor of UNION BANK OF CALIFORNIA, N.A., as agent (in such capacity, the "<u>Agent</u>") for the Lenders (as defined in the Credit Agreement referred to below, the "<u>Lenders</u>").

#### **RECITALS**

- A. The Agent and the Lenders have entered into that certain Credit Agreement dated as of even date herewith (said Agreement, as it may hereafter be amended, restated, supplemented or otherwise modified from time to time, being called the "<u>Credit Agreement</u>") with the Grantor.
- B. It is a condition precedent to the extension of credit by the Lenders under the Credit Agreement that the Grantor shall have executed and delivered this Agreement.
- C. Terms defined in the Credit Agreement and not otherwise defined herein have the same respective meanings when used herein, and the rules of interpretation set forth in Section 1.2 of the Credit Agreement are incorporated herein by reference. Schedule and Exhibit references are to this Agreement unless otherwise specified, and each such Schedule and Exhibit is incorporated herein. The words "include," "includes" and "including" shall be deemed to be followed by the phrase "without limitation".

#### **AGREEMENT**

NOW, THEREFORE, in order to induce the Lenders and the Agent to enter into the Credit Agreement and for other good and valuable consideration, the receipt and adequacy of which hereby is acknowledged, the Grantor hereby represents, warrants, covenants, agrees, assigns and grants as follows:

1. <u>Definitions</u>. Unless the context otherwise requires, terms defined in the Uniform Commercial Code of the State of California (the "<u>Uniform Commercial Code</u>") and not otherwise defined in this Agreement or in the Credit Agreement shall have the meanings defined for those terms in the Uniform Commercial Code. In addition, the following terms shall have the meanings respectively set forth after each:

"<u>Certificates</u>" means all certificates, instruments and other documents now or hereafter representing or evidencing any Pledged Securities or any Pledged Limited Liability Company Interests.

"Collateral" means all present and future right, title and interest of the Grantor in or to any property or assets whatsoever, whether now owned or existing or hereafter arising or acquired and wheresoever located, and all rights and powers of the Grantor to transfer any

interest in or to any property or assets whatsoever, including any and all of the following property:

- (a) All present and future accounts, accounts receivable, agreements, guarantees, contracts, leases, licenses, contract rights, health-care-insurance receivables, letter-of-credit rights and other rights to payment (collectively, the "Accounts"), together with all instruments, documents, chattel paper, security agreements, guaranties, undertakings, surety bonds, insurance policies, notes and drafts, all other supporting obligations, and all forms of obligations owing to the Grantor or in which the Grantor may have any interest, however created or arising;
- (b) All present and future general intangibles, payment intangibles, agreements, guarantees, contracts, contract rights, letter-of-credit rights, instruments, documents, leases, licenses and rights to payment; and all other forms of obligations owing to the Grantor or in which the Grantor may have any interest, however created or arising; all tax refunds of every kind and nature to which the Grantor now or hereafter may become entitled, however arising, all other refunds, all commitments to extend financing to the Grantor, and all deposits, goodwill, choses in action, trade secrets, computer programs, software, customer lists, trademarks, trade names, patents, licenses, copyrights, technology, processes, proprietary information, insurance proceeds and warranties including the Copyrights, the Patents, the Marks and the goodwill of the Grantor's business connected with and symbolized by the Marks;
- (c) All present and future demand, time, savings, passbook, deposit and like accounts (general or special) (collectively, the "<u>Deposit Accounts</u>") in which the Grantor has any interest which are maintained with any bank, savings and loan association, credit union or like organization, including each account listed on <u>Schedule E</u> (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement), and all money, cash and cash equivalents of the Grantor, whether or not deposited in any Deposit Account;
- (d) All present and future books and records, including books of account and ledgers of every kind and nature, all electronically recorded data relating to the Grantor or the business thereof, all receptacles and containers for such records, and all files and correspondence;
- (e) All present and future goods, including all furniture, fixtures, furnishings, machinery, automobiles, trucks, other vehicles, spare parts, supplies, equipment and other tangible property owned by the Grantor and used, held for use or useful in connection with its business, wherever located, and all other goods used in connection with or in the conduct of the Grantor's business or otherwise owned by the Grantor (collectively, the "Equipment");
- (f) All present and future inventory and merchandise, including all present and future goods held for sale or lease or to be furnished under a contract of service, all raw materials, work in process and finished goods, all packing materials, supplies and containers relating to or used in connection with any of the foregoing, and all bills of lading, warehouse receipts and documents of title relating to any of the foregoing (collectively, the "Inventory");
- (g) All present and future stocks, bonds, debentures, certificated and uncertificated securities, security entitlements, subscription rights, options, warrants, puts, calls, certificates, securities accounts, commodity contracts, commodity accounts, partnership interests, limited

20568574v3 - 2 -

liability company interests, joint venture interests and investment and/or brokerage accounts, and all other investment property, including the Certificates, the Pledged Securities, the Pledged Partnership Interests and the Pledged Limited Liability Company Interests, and all rights, preferences, privileges, dividends, distributions (in cash or in kind), redemption payments or liquidation payments with respect thereto;

- (h) All present and future accessions, appurtenances, components, repairs parts, spare parts, replacements, substitutions, additions, issue and/or improvements to or of or with respect to any of the foregoing;
  - (i) All other tangible and intangible personal property of the Grantor;
- (j) All rights, remedies, powers and/or privileges of the Grantor with respect to any of the foregoing; and
- (k) Any and all proceeds and products of the foregoing, including all money, accounts, general intangibles, deposit accounts, documents, instruments, letter-of-credit rights, investment property, chattel paper, goods, insurance proceeds and any other tangible or intangible property received upon the sale or disposition of any of the foregoing (collectively, the "Proceeds").

Notwithstanding anything herein to the contrary, in no event shall the security interest granted herein attach to, and the Collateral shall not include, (i) that portion of the outstanding Capital Stock of each Subsidiary organized or existing under the laws of a jurisdiction located outside of the United States that exceeds an aggregate of 65% of such Capital Stock entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2) or any successor regulation thereto), whether now owned or hereafter acquired and which may be issued and outstanding at any time and from time to time, or (ii) any governmental permit or any license, contract or agreement to which the Grantor is a party to the extent that the collateral assignment thereof or the creation of a security interest therein would constitute a breach of the terms of such permit, license, contract or agreement, or would permit the relevant Governmental Authority or any party to such agreement to terminate such permit, license, contract or agreement, except the Collateral expressly shall include any Proceeds of any of the foregoing assets; provided that, any permit, license, contract or agreement excluded in accordance with the foregoing shall cease to be so excluded (x) to the extent such term is, or would be (in the case of after-acquired property or changes to applicable law), rendered ineffective under Sections 9-406, 9-407, 9-408 or 9-409 of the UCC of any relevant jurisdiction (or any successor provision) or any other applicable law (including the Bankruptcy Code) or principles of equity (as determined by an applicable court); or (y) if the Grantor has obtained all of the consents of such Governmental Authority or the other parties to such license, contract or agreement necessary for the collateral assignment of, or creation of a security interest in, such permit, license, contract or agreement; provided further that, immediately upon the ineffectiveness, lapse or termination of any such term in any such permit, license, contract or agreement, the Collateral shall include, and the Grantor shall be deemed to have granted a security interest in, all such rights and interests as if such provision had never been in effect.

20568574v3 - 3 -

## "Copyrights" means all:

- (a) copyrights, whether or not published or registered under the Copyright Act of 1976, 17 U.S.C. Section 101 et seq., as the same shall be amended from time to time, and any predecessor or successor statute thereto (the "Copyright Act"), and applications for registration of copyrights, and all works of authorship and other intellectual property rights therein, including copyrights for computer programs, source code and object code data bases and related materials and documentation, and including the registered copyrights and copyright applications listed on Schedule B (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement), and (i) all renewals, revisions, derivative works, enhancements, modifications, updates, new releases and other revisions thereof, (ii) all income, royalties, damages and payments now and hereafter due and/or payable with respect thereto, including payments under all licenses entered into in connection therewith and damages and payments for past or future infringements thereof, (iii) the right to sue for past, present and future infringements thereof and (iv) all of the Grantor's rights corresponding thereto throughout the world;
- (b) rights under or interests in any copyright license agreements with any other party, whether the Grantor is a licensee or licensor under any such license agreement, including the copyright license agreements listed on <u>Schedule B</u> (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement), and the right to use the foregoing in connection with the enforcement of the Secured Party's rights under the Loan Documents; and
- (c) copyrightable materials now or hereafter owned by the Grantor, all tangible property embodying the copyrights or copyrightable materials described herein, and all tangible property covered by the licenses described in clause (b) hereof.

"<u>Limited Liability Company Acknowledgement</u>" shall have the meaning ascribed to it in Section 4(b) of this Agreement.

"<u>Limited Liability Company Assets</u>" means all assets, whether tangible or intangible and whether real, personal or mixed (including all limited liability company capital and interests in other limited liability companies), at any time owned or represented by any Limited Liability Company Interests.

"<u>Limited Liability Company Interests</u>" means the entire limited liability company interest at any time owned by the Grantor in any Pledged Entity.

"<u>Limited Liability Company Notice</u>" shall have the meaning ascribed to it in Section 4(b) of this Agreement.

"Marks" means all (i) trademarks, trademark registrations, interests under trademark license agreements, trade names, trademark applications, service marks, business names, trade styles, designs, logos and other source or business identifiers which are used in the United States or any state, territory or possession thereof, or in any other place, nation or jurisdiction anywhere in the world, including the trademark registrations and applications listed on Schedule B (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement), (ii) licenses pertaining to any such mark, whether the Grantor is a licensor or

20568574v3 - 4 -

licensee including the licenses listed on Schedule B (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement), (iii) all income, royalties, damages and payments now and hereafter due and/or payable with respect to any such mark or any such license, including damages and payments for past, present or future infringements thereof, (iv) rights to sue for past, present and future infringements thereof, (v) rights corresponding thereto throughout the world, (vi) all product specification documents and production and quality control manuals used in the manufacture of products sold under or in connection with such marks, (vii) all documents that reveal the name and address of all sources of supply of, and all terms of purchase and delivery for, all materials and components used in the production of products sold under or in connection with such marks, (viii) all documents constituting or concerning the then current or proposed advertising and promotion by the Grantor, its Subsidiaries or licensees of products sold under or in connection with such marks, including all documents that reveal the media used or to be used and the cost for all such advertising and (ix) renewals and proceeds of any of the foregoing.

"Material Copyrights" means Copyrights that are or shall be necessary in the operation of the Grantor's business (as reasonably determined by the Grantor or, upon the occurrence and during the continuance of an Event of Default, as determined by the Agent in its sole and absolute discretion) or the loss of which would reasonably be expected to have a Material Adverse Effect.

"Material Marks" means Marks that are or shall be necessary in the operation of the Grantor's business (as reasonably determined by the Grantor or, upon the occurrence and during the continuance of an Event of Default, as determined by the Agent in its sole and absolute discretion) or the loss of which would reasonably be expected to have a Material Adverse Effect.

"Material Patents" means Patents that are or shall be necessary in the operation of the Grantor's business (as reasonably determined by the Grantor or, upon the occurrence and during the continuance of an Event of Default, as determined by the Agent in its sole and absolute discretion) or the loss of which would reasonably be expected to have a Material Adverse Effect.

"Patents" means all (i) letters patent, design patents, utility patents, inventions and trade secrets, all patents and patent applications in the United States Patent and Trademark Office, and all interests under patent license agreements, including the inventions and improvements described and claimed therein, including those letters patent, design patents, utility patents, other patents, patent applications and patent license agreements listed on Schedule B (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement), (ii) licenses pertaining to any patent whether the Grantor is a licensor or licensee, (iii) income, royalties, damages and payments now and hereafter due and/or payable under and with respect thereto, including damages and payments for past, present or future infringements thereof, (iv) rights to sue for past, present and future infringements thereof, (v) rights corresponding thereto throughout the world and (vi) the reissues, divisions, continuations, renewals, extensions and continuations-in-part of any of the foregoing.

"<u>Pledged Collateral</u>" means the Certificates, the Pledged Securities, the Pledged Partnership Interests and the Pledged Limited Liability Company Interests.

20568574v3 - 5 -

"Pledged Entity" means each limited liability company set forth in Schedule A (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement), together with any other limited liability company in which the Grantor may have an interest at any time.

"Pledged Limited Liability Company Interests" means all interests in each Pledged Entity held by the Grantor, including those Limited Liability Company Interests identified in Schedule A (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement), including (i) all the capital thereof and the Grantor's interests in all profits, losses, Limited Liability Company Assets and other distributions in respect thereof; (ii) all other payments due or to become due to the Grantor in respect of such Limited Liability Company Interests; (iii) all of the Grantor's claims, rights, powers, privileges, authority, options, security interests, liens and remedies in respect of such Limited Liability Company Interests; (iv) all of the Grantor's rights to exercise and enforce every right, power, remedy, authority, option and privilege relating to such Limited Liability Company Interests; and (v) all other property delivered in substitution for or in addition to any of the foregoing and all certificates and instruments representing or evidencing such other property received, receivable or otherwise distributed in respect of or in exchange for any or all thereof.

"Pledged Partnership Interests" means all interests in any partnership or joint venture held by the Grantor, including those partnerships and/or joint ventures identified in Schedule A (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement) and all dividends, cash, instruments and other properties from time to time received, to be received or otherwise distributed in respect of or in exchange for any or all of such interests.

"<u>Pledged Securities</u>" means all shares of capital stock of any issuer in which the Grantor has an interest, including those shares of stock identified in <u>Schedule A</u> (as such Schedule may be supplemented from time to time in accordance with the terms of this Agreement) and all dividends, cash, instruments and other properties from time to time received, to be received or otherwise distributed in respect of or in exchange for any or all of such shares.

"Secured Party" means, collectively, the Agent, the Lenders and each counterparty to a Lender Hedging Agreement (including a Person who was a Lender at the time such Hedging Agreement was entered into).

- 2. <u>Creation of Security Interest</u>. The Grantor hereby assigns and pledges to the Agent for the ratable benefit of the Secured Party, and grants to the Agent for the ratable benefit of the Secured Party a security interest in and to, all right, title and interest of the Grantor in and to all presently existing and hereafter acquired Collateral.
- 3. <u>Security for Obligations</u>. This Agreement and the pledges made and security interests granted herein secure the prompt payment, in full in cash, and full performance of, the Obligations.

- 6 -

## 4. <u>Delivery of Pledged Collateral</u>.

- (a) Each Certificate shall, on (i) the Closing Date (with respect to Certificates existing on such date) and (ii) on the date of receipt or acquisition by the Grantor (with respect to Certificates received or acquired after the Closing Date, other than that portion of the outstanding Capital Stock of each foreign Subsidiary that exceeds an aggregate of 65% of such Capital Stock entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2) or any successor regulation thereto)), be delivered to and held by the Agent on behalf of the Secured Party and shall be in suitable form for transfer by delivery, or shall be accompanied by duly executed undated endorsements, instruments of transfer or assignment in blank, all in form and substance reasonably satisfactory to the Agent.
- (with respect to Limited Liability Company Interest, on (i) the Closing Date (with respect to Limited Liability Company Interests existing on such date) and (ii) the date of acquisition by the Grantor (with respect to Limited Liability Company Interests acquired after the Closing Date, other than that portion of the outstanding Capital Stock of each foreign Pledged Entity that exceeds an aggregate of 65% of such Capital Stock entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2) or any successor regulation thereto)) of any Limited Liability Company Interest, a notice substantially in the form set forth in Schedule G (the "Limited Liability Company Notice") shall be appropriately completed and delivered to each applicable Pledged Entity, notifying such Pledged Entity of the existence of this Agreement and the Grantor shall have received and delivered to the Agent a copy of such Limited Liability Company Notice, along with an acknowledgment in the form set forth in Schedule G (the "Limited Liability Company Acknowledgment"), duly executed by the relevant Pledged Entity.
- (c) The Agent shall have the right, upon the occurrence and during the continuance of an Event of Default, without notice to the Grantor, to transfer to or to direct the Grantor or any nominee of the Grantor to register or cause to be registered in the name of the Agent or any of its nominees any or all of the Pledged Collateral. In addition, the Agent shall have the right at any time to exchange certificates or instruments representing or evidencing Pledged Collateral for certificates or instruments of smaller or larger denominations.

#### 5. Further Assurances.

(a) At any time and from time to time, at the written request of the Agent, the Grantor shall execute and deliver to the Agent, at the Grantor's expense, all instruments, certificates and documents in form and substance reasonably satisfactory to the Agent, authorize the filing of such financing statements, and perform all such other acts as shall be necessary or desirable to fully perfect or protect or maintain, when filed, recorded, delivered or performed, the Secured Party's security interests granted pursuant to this Agreement or to enable the Agent and the Lenders to exercise and enforce their rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, the Grantor shall: (i) at the reasonable request of the Agent, mark conspicuously each document included in the Inventory and each other contract relating to the Accounts, and all chattel paper, instruments and other documents and each of their records pertaining to the Collateral with a legend, in form and substance reasonably satisfactory to the Agent, indicating that such document, contract, chattel paper, instrument or Collateral is subject to the security interests granted hereby; (ii) at the

20568574v3 - 7 -

request of the Agent, if any Account or contract or other writing relating thereto shall be evidenced by a promissory note or other instrument in a principal amount exceeding \$50,000 or if the aggregate amount of such promissory notes or other instruments exceeds \$100,000, deliver and pledge to the Agent, for the ratable benefit of the Secured Party, such note(s) and/or other instrument(s) duly endorsed and accompanied by duly executed undated instruments of transfer or assignment, all in form and substance reasonably satisfactory to the Agent; (iii) authorize the filing of such financing or continuation statements, or amendments thereto, and such other instruments or notices, as may be necessary or desirable, or as the Agent may reasonably request, in order to perfect and preserve, with the required priority, the security interests granted, or purported to be granted hereby; (iv) upon the Grantor's registration, or application therefor, of any Copyright under the Copyright Act, at the Agent's request execute and deliver to the Agent for recordation and filing in the United States Copyright Office a copy of this Agreement or another appropriate copyright mortgage document in form and substance reasonably satisfactory to the Agent; (v) upon the Grantor's registration, or application therefor, of any Patent or Mark, at the Agent's request execute and deliver to the Agent for recordation and filing in the United States Patent and Trademark Office a copy of this Agreement or another appropriate patent or trademark mortgage document, as applicable, in form and substance reasonably satisfactory to the Agent; (vi) at the request of the Agent, cause Control Agreements, in form and substance satisfactory to the Agent, to be executed by all parties necessary to establish "control" under the Uniform Commercial Code with respect to all deposit accounts and securities accounts of the Grantor; and (vii) at the request of the Agent, enter into arrangements in form and substance satisfactory to the Agent that are necessary to establish "control" under the UCC with respect to all investment property, letter-of-credit rights and electronic chattel paper of the Grantor.

- (b) At any time and from time to time, the Agent shall be entitled to file and/or record any or all such financing statements, instruments and documents held by it, and any or all such further financing statements, documents and instruments, relative to the Collateral or any part thereof in each instance, and to take all such other actions as the Agent may deem appropriate to perfect and to maintain perfected the security interests granted herein.
- (c) The Grantor hereby authorizes the Agent to file one or more financing or continuation statements, and amendments thereto, relative to all or any part of the Collateral without the signature of the Grantor where permitted by law. A carbon, photographic or other reproduction of this Agreement or any financing statement covering the Collateral or any part thereof shall be sufficient as a financing statement where permitted by law.
- (d) The Grantor shall furnish to the Agent concurrently with the delivery of the Covenant Compliance Certificate referred to in Section 5.2 of the Credit Agreement (or more frequently upon the reasonable request of the Agent or, upon the occurrence and during the continuance of an Event of Default, at any time requested by the Agent), supplements to the Schedules to this Agreement and other statements and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral as the Agent may reasonably request including the following: (i) if the Grantor obtains any rights or interests in any Deposit Accounts, securities accounts or other investment property (other than that referred to on Schedule A), the Grantor shall, in addition to all other acts required to be performed in respect thereof pursuant to this Agreement, supplement Schedule E to reflect such additional Deposit Accounts, securities accounts or other investment property; (ii) if the Grantor

20568574v3 - 8 -

publishes or registers, or applies for registration, of any copyright under the Copyright Act, the Grantor shall, in addition to all other acts required to be performed in respect thereof pursuant to this Agreement, supplement Schedule B to reflect the publication or registration of such copyright or application therefor; (iii) if the Grantor obtains any rights or interests in any Marks, the Grantor shall, in addition to all other acts required to be performed in respect thereof pursuant to this Agreement, supplement Schedule B to reflect such additional Marks; (iv) if the Grantor obtains any rights or interests in any Patents, the Grantor shall, in addition to all other acts required to be performed in respect thereof pursuant to this Agreement, supplement Schedule B to reflect such Patents; and (v) if the Grantor receives or acquires any additional shares of Capital Stock of any Person, any additional partnership interests in any partnership or joint venture or any additional Limited Liability Company Interests, the Grantor shall, in addition to all other acts required to be performed in respect thereof pursuant to this Agreement, supplement Schedule A to reflect such additional Pledged Collateral.

- (e) With respect to any Collateral consisting of certificates of title or the like as to which the Secured Party's security interest need be perfected by, or the priority thereof need be assured by, notation on the certificate of title pertaining to such Collateral, the Grantor will (i) promptly notify the Agent of the acquisition thereof and (ii) at the request of the Agent, cause such security interest to be noted on such certificate of title, in each case if the individual value of the Collateral evidenced by the certificate of title exceeds \$50,000 or if the aggregate value of all Collateral evidenced by certificates of title exceeds \$100,000; provided that upon the occurrence and during the continuance of an Event of Default, the Grantor shall cause the Agent's security interest to be noted on any certificate of title requested by the Agent, regardless of the value of the underlying Collateral.
- (f) With respect to any Collateral consisting of certificates of stock, securities, instruments, partnership or joint venture interests, interests in limited liability companies, or the like, the Grantor hereby consents and agrees that, upon the occurrence and during the continuance of an Event of Default, the issuers of, or obligors on, any such Collateral, or any registrar or transfer agent or trustee for any such Collateral, shall be entitled to the fullest extent permitted under applicable laws to accept the provisions of this Agreement as conclusive evidence of the right of the Agent to effect any transfer or exercise any right hereunder or with respect to any such Collateral subject to the terms hereof, notwithstanding any other notice or direction to the contrary heretofore or hereafter given by the Grantor or any other Person to such issuers or such obligors or to any such registrar or transfer agent or trustee.
- (g) Upon the Grantor's obtaining any rights or interests in any tangible chattel paper or electronic chattel paper having a value in excess of \$50,000 or if the aggregate value of all tangible chattel paper and electronic chattel paper exceeds \$100,000, the Grantor shall, in addition to all other acts required to be performed in respect thereof pursuant to this Agreement, promptly notify the Agent of such rights or interests; provided that upon the occurrence and during the continuance of an Event of Default, the Grantor shall, in addition to all other acts required to be performed in respect thereof pursuant to this Agreement, promptly notify the Agent of such rights or interests, regardless of its value.

20568574v3 - 9 -

- 6. <u>Voting Rights; Dividends; Etc.</u> So long as no Event of Default shall have occurred and be continuing:
- (a) <u>Voting Rights</u>. The Grantor shall be entitled to exercise any and all voting and other consensual rights pertaining to the Pledged Securities, the Pledged Partnership Interests and the Pledged Limited Liability Company Interests (including all voting, consent, administration, management and other rights and remedies under any partnership agreement or any operating agreement or otherwise with respect to the Pledged Securities, the Pledged Partnership Interests or the Pledged Limited Liability Company Interests), or any part thereof, for any purpose not in violation of the terms of this Agreement, the Credit Agreement or the other Loan Documents; <u>provided</u>, <u>however</u>, that the Grantor shall not exercise any such right if it would result in a Default.
- (b) <u>Dividend and Distribution Rights</u>. Subject to the terms of the Credit Agreement, the Grantor shall be entitled to receive and to retain and use any and all dividends or distributions paid in respect of the Pledged Securities, the Pledged Partnership Interests or the Pledged Limited Liability Company Interests; <u>provided</u>, <u>however</u>, that any and all
- (i) non-cash dividends or non-cash distributions in the form of certificated capital stock, certificated limited liability company interests, instruments or other property received, receivable or otherwise distributed in respect of, or in exchange for, any Pledged Securities, Pledged Partnership Interests or Pledged Limited Liability Company Interests,
- (ii) upon the occurrence and during the continuance of an Event of Default, dividends and other distributions paid or payable in cash in respect of any Pledged Securities, Pledged Partnership Interests or Pledged Limited Liability Company Interests in connection with a partial or total liquidation or dissolution or in connection with a reduction of capital, capital surplus or paid-in-surplus, and
- (iii) upon the occurrence and during the continuance of an Event of Default, cash paid, payable or otherwise distributed in redemption of, or in exchange for, any Pledged Securities, Pledged Partnership Interests or Pledged Limited Liability Company Interests,

shall forthwith be delivered to the Agent to be held as Collateral or applied to the Obligations in accordance with the Credit Agreement, as the Agent may elect; and, if received by the Grantor, shall be received in trust for the benefit of the Secured Party, be segregated from the other property of the Grantor and forthwith be delivered to the Agent in the same form as so received (with any necessary endorsements).

- 7. <u>Rights as to Pledged Collateral During Event of Default</u>. Upon delivery of notice to the Grantor that an Event of Default has occurred and is continuing:
- (a) <u>Voting, Dividend and Distribution Rights</u>. At the option of the Agent, all rights of the Grantor to exercise the voting and other consensual rights which it would otherwise be entitled to exercise pursuant to Section 6(a) above, and to receive the dividends and distributions which it would otherwise be authorized to receive and retain pursuant to Section 6(b) above, shall cease, and all such rights shall thereupon become vested in the Agent who shall thereupon

20568574v3 - 10 -

have the sole right to exercise such voting and other consensual rights and to receive and to hold as Pledged Collateral such dividends and distributions.

- (b) <u>Dividends and Distributions Held in Trust</u>. All dividends and other distributions which are received by the Grantor contrary to the provisions of Section 7(a) of this Agreement shall be received in trust for the benefit of the Secured Party, shall be segregated from other funds of the Grantor and forthwith shall be paid over to the Agent as Collateral in the same form as so received (with any necessary endorsements).
- (c) <u>Registration</u>. Determination by the Agent to exercise its right to sell pursuant to Section 16 hereof any or all of the Pledged Securities without registering the Pledged Securities under the Securities Act of 1933 shall not be deemed to be commercially unreasonable solely by virtue of the fact that the Pledged Securities were not so registered (provided that any such sale shall be conducted in accordance with the Uniform Commercial Code and other applicable laws).
- 8. <u>Irrevocable Proxy</u>. The Grantor hereby revokes all previous proxies (if any) with regard to the Pledged Securities, the Pledged Partnership Interests (if such interests are limited partnership interests) and the Pledged Limited Liability Company Interests and appoints the Agent as its proxyholder and attorney-in-fact to (i) attend and vote at any and all meetings of the shareholders of the corporation(s) which issued the Pledged Securities (whether or not transferred into the name of the Agent), and any adjournments thereof, held on or after the date of the giving of this proxy and to execute any and all written consents, waivers and ratifications of shareholders of such corporation(s) executed on or after the date of the giving of this proxy with the same effect as if the Grantor had personally attended the meetings or had personally voted its shares or had personally signed the written consents, waivers or ratification, and (ii) attend and vote at any and all meetings of the members of the Pledged Entities (whether or not such Pledged Limited Liability Company Interests or Pledged Partnership Interests are transferred into the name of the Agent), and any adjournments thereof, held on or after the date of the giving of this proxy and to execute any and all written consents, waivers and ratifications of the Pledged Entities executed on or after the date of the giving of this proxy with the same effect as if the Grantor had personally attended the meetings or had personally voted on its Limited Liability Company Interests or Pledged Partnership Interests or had personally signed the consents, waivers or ratifications; provided, however, that the revocation of existing proxies (if any) shall not be effective until, and the Agent as proxyholder and attorney-in-fact shall have rights hereunder only upon, the occurrence and during the continuance of an Event of Default. The Grantor hereby authorizes the Agent to substitute another Person (which Person shall be a successor to the rights of the Agent hereunder or a nominee appointed by the Agent to serve as proxyholder) as the proxyholder and, upon the occurrence or during the continuance of any Event of Default, hereby authorizes and directs the proxyholder to file this proxy and the substitution instrument with the secretary of the appropriate corporation, limited partnership or limited liability company. This proxy is coupled with an interest and is irrevocable until such time each Commitment, each Letter of Credit and any applicable bankruptcy preference period has expired and all Obligations have been paid in full.

20568574v3 - 11 -

### 9. Copyrights.

- (a) <u>Royalties</u>. The Grantor hereby agrees that the use by the Agent or any Lender of the Copyrights as authorized hereunder in connection with the Agent's or the Lenders' exercise of their rights and remedies hereunder shall be without any liability for royalties or other related charges from the Agent or the Lenders to the Grantor.
- (b) Restrictions on Future Agreements. Subject to the terms hereof and of the Credit Agreement, the Grantor shall be permitted to manage, license and administer its Copyrights and to become a licensee of other copyrights in such manner as the Grantor in its reasonable business judgment deems desirable; provided, however, that the Grantor will not, without the Agent's prior written consent (which consent shall not be unreasonably withheld or delayed), (i) abandon any Material Copyright in which the Grantor now owns or hereafter acquires any rights or interests or (ii) enter into any license agreements in which the Grantor licenses any of its Material Copyrights to another Person.
- (c) <u>Duties of Grantor</u>. The Grantor agrees to: (i) prosecute diligently any Material Copyright, (ii) upon the occurrence and during the continuance of an Event of Default, make application for registration of such uncopyrighted but copyrightable material owned by the Grantor as the Agent reasonably deems appropriate, (iii) place notices of copyright on all copyrightable property produced or owned by the Grantor embodying the Material Copyrights and cause its licensees to do the same, and (iv) take all action necessary (as reasonably determined by the Grantor or, upon the occurrence and during the continuance of an Event of Default, as determined by the Agent in its sole and absolute discretion) to preserve and maintain all rights in the Material Copyrights, including making timely filings for renewals and extensions of such Copyrights and diligently monitoring unauthorized use thereof. Any expenses incurred in connection with the foregoing shall be borne by the Grantor. The Grantor shall give proper statutory notice in connection with its use of each Material Copyright to the extent necessary (as reasonably determined by the Grantor or, upon the occurrence and during the continuance of an Event of Default, as determined by the Agent in its sole and absolute discretion) for the protection thereof. The Grantor shall notify the Agent of any suits it commences to enforce any Copyright and shall provide the Agent with copies of any documents reasonably requested by the Agent relating to such suits. Neither the Agent nor the Lenders shall have any duty with respect to the Copyrights other than to act lawfully and without gross negligence or willful misconduct. Without limiting the generality of the foregoing, neither the Agent nor the Lenders shall be under any obligation to take any steps necessary to preserve rights in the Copyrights against any other party, but the Agent may do so at its option upon the occurrence and during the continuance of an Event of Default, and all reasonable costs and out-of-pocket expenses incurred in connection therewith shall be for the account of the Grantor and shall be added to the Obligations.

#### 10. Patents and Marks.

(a) <u>Royalties</u>. The Grantor hereby agrees that any rights granted hereunder to the Agent or any Lender with respect to Patents and Marks shall be applicable to all territories in which the Grantor has the right to use such Patents and Marks, from time to time, and without any liability for royalties or other related charges from the Agent or the Lenders to the Grantor.

20568574v3 - 12 -

- (b) Restrictions on Future Agreements. Subject to the terms hereof and of the Credit Agreement, the Grantor shall be permitted to manage, license and administer its Patents and Marks and to become a licensee of other patents and trademarks in such manner as the Grantor in its reasonable business judgment deems desirable; provided, however, that the Grantor will not, without the Agent's prior written consent (which consent shall not be unreasonably withheld or delayed), (i) abandon any Material Patent or Material Mark in which the Grantor now owns or hereafter acquires any rights or interests or (ii) enter into any license agreements pursuant to which the Grantor licenses any Material Patent or Material Mark to another Person.
- (c) <u>Duties of Grantor</u>. The Grantor agrees to: (i) prosecute diligently any Material Patent and Material Mark, (ii) upon the occurrence and during the continuance of an Event of Default, make application on unpatented but patentable inventions owned by the Grantor and on unregistered Marks, as the case may be, as the Agent reasonably deems appropriate, (iii) file and prosecute opposition and cancellation proceedings in respect of Material Patents and Material Marks if reasonably determined by the Grantor to be necessary (or upon the occurrence and during the continuance of an Event of Default, as determined by the Agent in its sole and absolute discretion) and (iv) take all action necessary (as reasonably determined by the Grantor or, upon the occurrence and during the continuance of an Event of Default, as determined by the Agent in its sole and absolute discretion) to preserve and maintain all rights in the Material Patents and Material Marks, including making timely filings for renewals and extensions of such Patents and Marks and diligently monitoring unauthorized use thereof. Any expenses incurred in connection with the foregoing shall be borne by the Grantor. The Grantor shall give proper statutory notice in connection with its use of each Material Mark and each Material Patent to the extent necessary (as reasonably determined by the Grantor or, upon the occurrence and during the continuance of an Event of Default, as determined by the Agent in its sole and absolute discretion) for the protection thereof. The Grantor shall notify the Agent of any suit it commences to enforce any Patent or Mark and shall provide the Agent with copies of any documents reasonably requested by the Agent relating to such suit. Neither the Agent nor the Lenders shall have any duty with respect to the Patents and Marks other than to act lawfully and without gross negligence or willful misconduct. Without limiting the generality of the foregoing, neither the Agent nor the Lenders shall be under any obligation to take any steps necessary to preserve rights in the Patents and Marks against any other party, but the Agent may do so at its option upon the occurrence and during the continuance of an Event of Default, and all reasonable costs and out-of-pocket expenses incurred in connection therewith shall be for the account of the Grantor and shall be added to the Obligations.
- 11. <u>Grantor's Representations and Warranties</u>. The Grantor represents and warrants as follows:
- (a) (i) <u>Schedule C</u> sets forth each location at which (A) Inventory and/or Equipment is located and (B) the Grantor conducts business and, with respect to each such location, whether the Grantor is duly qualified and in good standing under the laws of such location; (ii) the chief executive office of the Grantor, where the Grantor keeps its records concerning the Collateral and the chattel paper evidencing the Collateral, is located at the address set forth for the Grantor on <u>Schedule D</u>; (iii) all records concerning any Accounts and all originals of all contracts and other writings which evidence any Accounts are located at the addresses listed on <u>Schedule D</u>; (iv) the Grantor has exclusive possession and control of the Equipment and the Inventory, except

20568574v3 - 13 -

as set forth on Schedule C (and provided that Schedule C shall provide, with respect to such Equipment and Inventory, its description, location and approximate value (as reasonably determined by the Grantor)); (v) the Grantor's exact legal name, and the place of formation of the Grantor, are as set forth in the preamble to this Agreement; (vi) each trade name or other fictitious name under which the Grantor conducts business, or has conducted business at any time during the five years immediately preceding the Closing Date, is set forth on Schedule 3.6 to the Credit Agreement; and (vii) the Grantor's state organizational identification number, if any, is set forth on Schedule F.

- The Grantor is the legal and beneficial owner of the Collateral free and clear of all (b) Liens except for Liens permitted by Section 6.3 of the Credit Agreement. The Grantor has the power, authority and legal right to grant the security interests in the Collateral purported to be granted hereby, and to execute, deliver and perform this Agreement. The pledge of the Collateral pursuant to this Agreement creates a valid security interest in the Collateral. Upon the filing of an appropriate financing statement in the filing office set forth on Schedule F, the recordation of appropriate documentation with the United States Copyright Office and the United States Patent and Trademark Office, as applicable, the execution of Control Agreements with respect to the deposit accounts and the securities accounts of the Grantor, the giving of a Limited Liability Company Notice to the Pledged Entities (and the receipt of a Limited Liability Company Acknowledgment from such Pledged Entities), the execution of bailee letters with respect to certain Collateral held by third parties, the Agent's exercise of "control" under the Uniform Commercial Code with respect to all investment property, letter-of-credit rights and electronic chattel paper of the Grantor, the delivery to the Agent of the Certificates, and the notation of the Secured Party's security interest on certificates of title to the extent required for perfection or priority, as the case may be, the Agent for the ratable benefit of the Secured Party will have a first-priority perfected security interest (except for Liens permitted by Section 6.3 of the Credit Agreement) in the Collateral to the extent a security interest in such Collateral can be perfected by such filings, recordations, the giving of such notices (and receipt of such acknowledgments), letters, agreements, the exercise of control, the delivery of such Certificates and the notation of such security interest.
- (c) The Pledged Securities and the Pledged Limited Liability Company Interests have been duly authorized and validly issued and are fully paid and nonassessable. All of the Pledged Securities and Pledged Limited Liability Company Interests are in certificated form and are securities (as contemplated by Division 8 of the Uniform Commercial Code).
- (d) No consent of any Person, including any partner in a partnership with respect to which the Grantor has pledged its interest as a Pledged Partnership Interest or any member in a Pledged Entity, is required for the pledge by the Grantor of the Collateral except for those consents which have been made or obtained prior to the effectiveness of such pledge.
- (e) The Pledged Securities described on <u>Schedule A</u> constitute (i) all of the shares of capital stock of any Person owned by the Grantor and (ii) that percentage of the issued and outstanding shares of the respective issuers thereof indicated on <u>Schedule A</u>, and there is no other class of shares issued and outstanding of the respective issuers thereof except as set forth on <u>Schedule A</u>. The Pledged Partnership Interests described on <u>Schedule A</u> constitute (i) all of the partnerships or joint ventures in which the Grantor has an interest and (ii) the Grantor's

20568574v3 - 14 -

respective percentage interests in each such partnership or joint venture are as set forth on such Schedule A, and there is no other class of interests therein issued and outstanding except as set forth on Schedule A. The Pledged Limited Liability Company Interests described on Schedule A constitute (i) all of the Limited Liability Company Interests owned by the Grantor and (ii) the Grantor's respective percentage ownership interests in each such Pledged Entity are as set forth on Schedule A, and there is no other class of interests therein issued and outstanding except as set forth on Schedule A.

- (f) As of the Closing Date, no authorization, approval or other action by, and no notice to or filing with, any Governmental Authority (other than (i) such authorizations, approvals and other actions as have already been taken and are in full force and effect, (ii) the filing of a UCC-1 financing statement in favor of the Agent with the Delaware Secretary of State indicating the Grantor as a debtor and (iii) the recordation and filing in the United States Patent and Trademark Office of the U.S. Marks listed in Schedule B) is required (A) for the pledge of the Collateral or the grant of the security interest in the Collateral by the Grantor hereby or for the execution and delivery or performance of this Agreement by the Grantor, or (B) for the exercise by the Agent of the voting rights in the Pledged Securities, the Pledged Partnership Interests and the Pledged Limited Liability Company Interests or of any other rights or remedies in respect of the Collateral hereunder except as may be required in connection with any disposition of Collateral consisting of securities by laws affecting the offering and sale of securities generally.
- (g) The Grantor does not own, is not a licensee of, nor has the Grantor applied for any Copyrights, Marks or Patents, other than those set forth on Schedule B. Except as set forth on Schedule B, none of such Copyrights, Marks or Patents has been registered with any Governmental Authority, nor has an application for such registration been made.
- (h) <u>Schedule E</u> sets forth (i) all of the Grantor's deposit accounts, (ii) all of the Grantor's securities accounts and other investment property (other than that referred to on <u>Schedule A</u>) and (iii) all letters of credit issued for the benefit of the Grantor. As of the Closing Date, the Grantor has no chattel paper or electronic chattel paper.
- (i) The Grantor does not own or lease any vehicle having a fair market value in excess of \$50,000.
- 12. <u>Grantor's Covenants</u>. In addition to the other covenants and agreements set forth herein and in the other Loan Documents, the Grantor covenants and agrees as follows:
- (a) The Grantor will pay, discharge or otherwise satisfy at or before maturity or before they become delinquent, as the case may be, all its taxes, charges, Liens and assessments against the Collateral except where the amount or validity thereof is currently being contested in good faith by appropriate proceedings and reserves in conformity with GAAP with respect thereto have been provided on the books of the Grantor and except as would not reasonably be expected to have a Material Adverse Effect.

20568574v3 - 15 -

- (b) The Collateral will not be used in violation of any material Requirement of Law applicable to the Grantor, nor used in any way that will void or impair any insurance required under the Credit Agreement to be carried in connection therewith.
- (c) The Grantor shall keep all Collateral in good working order and condition (ordinary wear and tear and casualty excepted) and from time to time make all necessary and proper repairs, renewals, replacements, additions and improvements thereto, subject to Section 6.5 of the Credit Agreement.
- (d) The Grantor will promptly notify the Agent in writing in the event of any material damage to the Collateral from any source whatsoever including prompt written notice of all insurance and condemnation proceeds received by it or any Subsidiary on or after the Closing Date in excess of \$50,000 per occurrence.
- The Grantor will (i) not establish any location of Inventory or Equipment not listed on Schedule C, (ii) not move its principal place of business, chief executive office or any other office listed on Schedule D, (iii) not adopt, use or conduct business under any trade name or other corporate or fictitious name not disclosed on Schedule 3.6 to the Credit Agreement, (iv) not acquire or open, as applicable, any deposit account or securities account, or acquire any letter of credit issued for the benefit of the Grantor, (v) not create any chattel paper having a value in excess of \$50,000 (or an aggregate value of \$100,000) without placing a legend on the chattel paper reasonably acceptable to the Agent indicating the Secured Party's security interest therein, (vi) not change its legal name, its place of incorporation, formation or organization (as applicable) or its state organizational identification number, from those specified in the preamble to this Agreement and Schedule F; (vii) preserve its legal existence and not, in one transaction or a series of related transactions, merge into or consolidate with any other Person, or sell all or substantially all of its assets; (viii) not permit any issuer of Pledged Securities to issue any securities in uncertificated form or seek to convert all or any part of any Pledged Securities into uncertificated form (as contemplated by Division 8 of the Uniform Commercial Code), (ix) not permit any issuer of Pledged Limited Liability Company Interests to issue any Limited Liability Company Interests in uncertificated form, seek to convert all or any part of any Limited Liability Company Interests into uncertificated form or render any Limited Liability Company Interests to no longer be a security (as contemplated by Division 8 of the Uniform Commercial Code), or (x) not permit any issuer of Pledged Securities or any Pledged Entity to issue any additional Capital Stock or membership interests or any other rights or options with respect thereto, as applicable, other than to the Grantor, except, in each case set forth in clauses (i)-(x) above, upon not less than 30 days' prior written notice to the Agent and the Grantor's prior compliance with all applicable requirements of Section 5 hereof necessary to perfect the Secured Party's security interests hereunder, and in each case subject to the terms of the Credit Agreement.
- of a third party unless written notice of the Secured Party's security interest therein has been given to such third party, and such third party has acknowledged in writing that it is holding such Collateral for the benefit of the Secured Party, such notice and acknowledgement to be in form acceptable to the Agent; provided that (i) the Agent shall not exercise any right under such notice and acknowledgment to take possession of such Equipment or Inventory unless and until an Event of Default has occurred and is continuing and (ii) the Grantor shall not be required to

20568574v3 - 16 -

deliver such notice and acknowledgment to the Agent unless the value of the Equipment and Inventory in the possession of a third party is equal to or more than \$250,000.

- (g) Except as permitted by Section 6.4 of the Credit Agreement, the Grantor shall not withdraw as a member of any Pledged Entity or a partner in any partnership with respect to which the Grantor has pledged any interest, or file or pursue or take any action which may, directly or indirectly, cause a dissolution or liquidation of or with respect to any Pledged Entity or any such partnership or seek a partition of any property of any Pledged Entity or any such partnership.
- (h) The Grantor shall promptly notify the Agent in writing in the event that the Grantor becomes a licensee of any Material Copyright, Material Mark or Material Patent, other than those set forth on Schedule B, and shall execute any and all documents, instruments or agreements and perform any and all actions reasonably requested by the Agent to give a collateral assignment thereof including procuring the consent of the licensor thereto.
- Agent's Rights Regarding Collateral. At any time and from time to time, the Agent may, to the extent necessary or desirable to protect the security hereunder, but the Agent shall not be obligated to: (a) (whether or not a Default has occurred) itself or through its representatives, visit and inspect the Grantor's properties and examine and make abstracts from any of its books and records at any reasonable time to discuss the business, operations, properties and financial and other condition of the Grantor with officers of the Grantor or (b) if an Event of Default has occurred and is continuing, at the expense of the Grantor, perform any obligation of the Grantor under this Agreement. At any time and from time to time after an Event of Default has occurred and is continuing, at the expense of the Grantor, the Agent (for the benefit of the Secured Party) may, to the extent necessary or desirable to protect the security hereunder, but the Agent shall not be obligated to: (i) notify obligors on the Collateral that the Collateral has been assigned as security to the Agent for the benefit of the Secured Party; (ii) at any time and from time to time request from obligors on the Collateral, in the name of the Grantor or in the name of the Secured Party, information concerning the Collateral and the amounts owing thereon; and (iii) direct obligors under the contracts included in the Collateral to which the Grantor is a party to direct their performance to the Agent. The Grantor shall keep proper books and records and accounts in which full, true and correct entries in conformity with GAAP and all material applicable Requirements of Law shall be made of all material dealings and transactions pertaining to the Collateral. Neither the Agent nor the Lenders shall be under any duty or obligation whatsoever to take any action to preserve any rights of or against any prior or other parties in connection with the Collateral, to exercise any voting rights or managerial rights with respect to any Collateral or to make or give any presentments for payment, demands for performance, notices of non-performance, protests, notices of protest, notices of dishonor or notices of any other nature whatsoever in connection with the Collateral or the Obligations. Neither the Agent nor the Lenders shall be under any duty or obligation whatsoever to take any action to protect or preserve the Collateral or any rights of the Grantor therein, or to make collections or enforce payment thereon, or to participate in any foreclosure or other proceeding in connection therewith. Nothing contained herein shall constitute an assumption by the Agent or the Lenders of any obligations of the Grantor under any contracts assigned hereunder unless the Agent shall have given written notice to the counterparty to such assigned contract of the

20568574v3 - 17 -

Agent's intention to assume such contract on behalf of the Secured Party. The Grantor shall continue to be liable for performance of its obligations under such contracts.

Nothing contained herein shall be construed to make the Agent or any Lender liable as a stockholder of any corporation, member of any Pledged Entity or partner in any partnership with respect to which the Grantor has pledged its interests in Pledged Securities, Pledged Limited Liability Company Interests or Pledged Partnership Interests, and neither the Agent nor any Lender by virtue of this Agreement or otherwise (except as referred to in the following sentence) shall have any of the duties, obligations or liabilities of a stockholder of any such corporation, member of any such Pledged Entity or partner in such partnership. The parties hereto expressly agree that, unless the Agent shall become the absolute owner of any Pledged Securities or Pledged Limited Liability Company Interests or Pledged Partnership Interests pursuant hereto, this Agreement shall not be construed as creating a partnership or joint venture among the Agent, any Lender, any such corporation, any such Pledged Entity or any such partnership and/or the Grantor. Except as provided in the immediately preceding sentence, the Agent, by accepting this Agreement, does not intend to become a stockholder of any corporation, member of any Pledged Entity or partner in any partnership with respect to which the Grantor has pledged its interests in any Pledged Securities, Pledged Limited Liability Company Interests or Pledged Partnership Interests, or otherwise be deemed to be a co-venturer with respect to the Grantor or any such corporation, Pledged Entity or partnership, either before or after an Event of Default shall have occurred.

14. Collections on the Collateral. Except as provided to the contrary in the Credit Agreement, the Grantor shall have the right to use and to continue to make collections on and receive dividends and other proceeds of all of the Collateral in the ordinary course of business so long as no Event of Default shall have occurred and be continuing. Upon the occurrence and during the continuance of an Event of Default, at the option of the Agent, the Grantor's right to make collections on and receive dividends and other proceeds of the Collateral and to use or dispose of such collections and proceeds shall terminate, and any and all dividends, proceeds and collections, including all partial or total prepayments, then held or thereafter received on or on account of the Collateral will be held or received by the Grantor in trust for the Secured Party and immediately delivered in kind to the Agent (duly endorsed to the Agent, if required), to be applied to the Obligations or held as Collateral, as the Agent shall elect. Upon the occurrence and during the continuance of an Event of Default, the Agent shall have the right at all times to receive, receipt for, endorse, assign, deposit and deliver, in the name of the Agent or the Secured Party or in the name of the Grantor, any and all checks, notes, drafts and other instruments for the payment of money constituting proceeds of or otherwise relating to the Collateral; and the Grantor hereby authorizes the Agent to affix, by facsimile signature or otherwise, the general or special endorsement of the Grantor, in such manner as the Agent shall deem advisable, to any such instrument in the event the same has been delivered to or obtained by the Agent without appropriate endorsement, and the Agent and any collecting bank are hereby authorized to consider such endorsement to be a sufficient, valid and effective endorsement by the Grantor, to the same extent as though it were manually executed by the duly authorized representatives of the Grantor, regardless of by whom or under what circumstances or by what authority such endorsement actually is affixed, without duty of inquiry or responsibility as to such matters, and the Grantor hereby expressly waives demand, presentment, protest and notice of protest or dishonor and all other notices of every kind and nature with respect to any such instrument.

20568574v3 - 18 -

15. Possession of Collateral by Agent. All the Collateral now, heretofore or hereafter delivered to the Agent shall be held by the Agent in its possession, custody and control. Any or all of the Collateral delivered to and held and maintained by the Agent constituting cash or Cash Equivalents shall, prior to the occurrence of any Event of Default, upon written request of the Grantor, be held in an interest-bearing account with the Agent, and shall be invested in Cash Equivalents. Nothing herein shall obligate the Agent to obtain any particular return thereon. Upon the occurrence and during the continuance of an Event of Default, whenever any of the Collateral is in the Agent's possession, custody or control, the Agent may use, operate and consume the Collateral, whether for the purpose of preserving and/or protecting the Collateral, or for the purpose of performing any of the Grantor's obligations with respect thereto, or otherwise. and, subject to the terms of Section 9.7 of the Credit Agreement, any or all of the Collateral delivered to the Agent constituting cash or Cash Equivalents shall be applied by the Agent to payment of the Obligations or held as Collateral, as the Agent shall elect. The Agent may at any time deliver or redeliver the Collateral or any part thereof to the Grantor, and the receipt of any of the same by the Grantor shall be complete and full acquittance for the Collateral so delivered, and the Agent thereafter shall be discharged from any liability or responsibility arising after such delivery to the Grantor. So long as the Agent exercises reasonable care with respect to any Collateral in its possession, custody or control, neither the Agent nor the Lenders shall have any liability for any loss of or damage to any Collateral, and in no event shall the Agent or the Lenders have liability for any diminution in value of the Collateral occasioned by economic or market conditions or events. The Agent shall be deemed to have exercised reasonable care within the meaning of the preceding sentence if the Collateral in the possession, custody or control of the Agent is accorded treatment substantially equal to that which the Agent accords similar property for its own account, it being understood that neither the Agent nor the Lenders shall have any responsibility for (i) ascertaining or taking action with respect to calls, conversions, exchanges, maturities, tenders or other matters relating to any Collateral, whether or not the Agent or any Lender has or is deemed to have knowledge of such matters, or (ii) taking any necessary steps to preserve rights against any Person with respect to any Collateral.

#### 16. Remedies.

Rights Upon Event of Default. Upon the occurrence and during the continuance of an Event of Default, the Grantor shall be in default hereunder and the Agent for the benefit of the Secured Party shall have, in any jurisdiction where enforcement is sought, in addition to all other rights and remedies that the Agent on behalf of the Secured Party may have under this Agreement and under applicable laws or in equity, all rights and remedies of a secured party under the Uniform Commercial Code as enacted in any such jurisdiction in effect at that time, and in addition the following rights and remedies, all of which may be exercised with or without notice to the Grantor except such notice as may be specifically required by applicable law: (i) to foreclose the Liens created hereunder or under any other Loan Document by any available judicial procedure or without judicial process; (ii) to enter any premises where any Collateral may be located for the purpose of securing, protecting, inventorying, appraising, inspecting, repairing, preserving, storing, preparing, processing, taking possession of or removing the same; (iii) to sell, assign, lease or otherwise dispose of any Collateral or any part thereof, either at public or private sale or at any broker's board, in lot or in bulk, for cash, on credit or otherwise, with or without representations or warranties and upon such terms as shall be commercially reasonable; (iv) to notify obligors on the Collateral that the Collateral has been assigned to the

20568574v3 - 19 -

Agent for the benefit of the Secured Party and that all payments thereon, or performance with respect thereto, are to be made directly and exclusively to the Agent for the account of the Secured Party; (v) to collect by legal proceedings or otherwise all dividends, distributions, interest, principal or other sums now or hereafter payable upon or on account of the Collateral; (vi) to enter into any extension, reorganization, disposition, merger or consolidation agreement, or any other agreement relating to or affecting the Collateral, and in connection therewith the Agent may deposit or surrender control of the Collateral and/or accept other property in exchange for the Collateral as the Agent deems appropriate; (vii) to settle, compromise or release, on terms acceptable to the Agent, in whole or in part, any amounts owing on the Collateral and/or any disputes with respect thereto; (viii) to extend the time of payment, make allowances and adjustments and issue credits in connection with the Collateral in the name of the Agent for the benefit of the Secured Party or in the name of the Grantor; (ix) to enforce payment and prosecute any action or proceeding with respect to any or all of the Collateral and take or bring, in the name of the Secured Party or in the name of the Grantor, any and all steps, actions, suits or proceedings deemed necessary or desirable by the Agent to effect collection of or to realize upon the Collateral, including any judicial or nonjudicial foreclosure thereof or thereon, and the Grantor specifically consents to any nonjudicial foreclosure of any or all of the Collateral or any other action taken by the Secured Party which may release any obligor from personal liability on any of the Collateral, and any money or other property received by the Agent in exchange for or on account of the Collateral, whether representing collections or proceeds of Collateral, and whether resulting from voluntary payments or foreclosure proceedings or other legal action taken by Agent or the Grantor may be applied by the Agent, without notice to the Grantor, to the Obligations in such order and manner as the Agent in its sole discretion shall determine; (x) to insure, protect and preserve the Collateral; (xi) to exercise all rights, remedies, powers or privileges provided under any of the other Loan Documents; and (xii) to remove, from any premises where the same may be located, the Collateral and any and all documents, instruments, files and records, and any receptacles and cabinets containing the same, relating to the Collateral, and the Agent may, at the cost and expense of the Grantor, use such of its supplies, equipment, facilities and space at its places of business as may be necessary or appropriate to properly administer, process, store, control, prepare for sale or disposition and/or sell or dispose of the Collateral or to properly administer and control the handling of collections and realizations thereon, and the Agent shall be deemed to have a rent-free tenancy of any premises of the Grantor for such purposes and for such periods of time as reasonably required by the Agent. The Grantor will, at the Agent's request, assemble the Collateral and make it available to the Agent at places which the Agent may designate, whether at the premises of the Grantor or elsewhere, and will make available to the Agent, free of cost, all premises, equipment and facilities of the Grantor for the purpose of the Agent's taking possession of the Collateral or storing the same or removing or putting the Collateral in salable form or selling or disposing of the same. The Agent has no obligation to clean-up or otherwise prepare the Collateral for sale.

(b) <u>Possession by Agent</u>. Upon the occurrence and during the continuance of an Event of Default, the Agent also shall have the right, without notice or demand, either in person, by agent or by a receiver to be appointed by a court in accordance with the provisions of applicable law (and the Grantor hereby expressly consents, to the fullest extent permitted by applicable law, upon the occurrence and during the continuance of an Event of Default to the appointment of such a receiver), and, to the extent permitted by applicable law, without regard to the adequacy of any security for the Obligations, to operate the business of the Grantor, by, inter-

20568574v3 - 20 -

<u>alia</u>, taking possession of the Collateral or any part thereof and to collect and receive the rents, issues, profits, income and proceeds thereof, pending the exercise of any and all other rights and remedies available to the Agent under this Agreement and/or at law or in equity. The operation of the Grantor's business and the taking possession of the Collateral by the Agent shall not cure or waive any Event of Default or notice thereof or invalidate any act done pursuant to such notice. The rights, remedies and powers of any receiver appointed by a court shall be as ordered by said court.

- (c) <u>Sale of Collateral</u>. Any public or private sale or other disposition of the Collateral may be held at any office of Agent, or at the Grantor's place of business, or at any other place permitted by applicable law, and without the necessity of the Collateral's being within the view of prospective purchasers. The Agent may direct the order and manner of sale of the Collateral, or portions thereof, as it in its sole and absolute discretion may determine provided such sale is commercially reasonable, and the Grantor expressly waives, to the extent permitted by applicable law, any right to direct the order and manner of sale of any Collateral. The Agent or any Person acting on the Agent's behalf may bid and purchase at any such sale or other disposition. In addition to the other rights of the Agent hereunder, the Grantor hereby grants to the Agent a license or other right to use, without charge, but only after the occurrence and during the continuance of an Event of Default, the Grantor's labels, copyrights, patents, rights of use of any name, trade names, trademarks and advertising matter, or any property of a similar nature, including the Copyrights, the Patents and the Marks, in advertising for sale and selling any Collateral. The Secured Party may comply with any applicable state or federal law requirements in connection with a disposition of the Collateral and compliance will not be considered adversely to affect the commercial reasonableness of any sale of the Collateral.
- in value or is of a type customarily sold on a recognized market, the Agent will give the Grantor reasonable notice of the time and place of any public sale thereof or of the time and place on or after which any private sale thereof is to be made. The requirement of reasonable notice conclusively shall be met if such notice is mailed, certified mail, postage prepaid, to the Grantor at its address set forth in the Credit Agreement, or delivered or otherwise sent to the Grantor, at least ten days before the date of the sale. The Grantor expressly waives, to the fullest extent permitted by applicable law, any right to receive notice of any public or private sale of any Collateral or other security for the Obligations except as expressly provided for in this paragraph. The Agent shall not be obligated to make any sale of the Collateral if it shall determine not to do so regardless of the fact that notice of sale of the Collateral may have been given. The Agent may, without notice or publication, except as required by applicable law, adjourn the sale from time to time by announcement at the time and place fixed for sale, and such sale may, without further notice (except as required by applicable law), be made at the time and place to which the same was so adjourned.
- (e) <u>Private Sales</u>. With respect to any Collateral consisting of securities, partnership interests, membership interests, joint venture interests or the like, and whether or not any of such Collateral has been effectively registered under the Securities Act of 1933, as amended, or other applicable laws, the Agent may, in its sole and absolute discretion, sell all or any part of such Collateral at private sale in such manner and under such circumstances as the Agent may deem necessary or advisable in order that the sale may be lawfully conducted in a commercially

20568574v3 - 21 -

reasonable manner. Without limiting the foregoing, the Agent may (i) approach and negotiate with a limited number of potential purchasers, and (ii) restrict the prospective bidders or purchasers to persons who will represent and agree that they are purchasing such Collateral for their own account for investment and not with a view to the distribution or resale thereof. In the event that any such Collateral is sold at private sale, the Grantor agrees to the extent permitted by applicable law that if such Collateral is sold for a price which is commercially reasonable, then (A) the Grantor shall not be entitled to a credit against the Obligations in an amount in excess of the purchase price, and (B) neither the Agent nor the Lenders shall incur any liability or responsibility to the Grantor in connection therewith, notwithstanding the possibility that a substantially higher price might have been realized at a public sale. The Grantor recognizes that a ready market may not exist for such Collateral if it is not regularly traded on a recognized securities exchange, and that a sale by the Agent of any such Collateral for an amount less than a pro rata share of the fair market value of the issuer's assets minus liabilities may be commercially reasonable in view of the difficulties that may be encountered in attempting to sell a large amount of such Collateral or Collateral that is privately traded.

- Agent on behalf of the Secured Party shall have the right to assign, transfer and deliver to the purchaser or purchasers thereof the Collateral so sold. Each such purchaser at any such sale shall hold the Collateral so sold absolutely free from any claim or right upon the part of the Grantor or any other Person claiming through the Grantor, and the Grantor hereby waives (to the extent permitted by applicable law) all rights of redemption, stay and appraisal which it now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted. If the sale of all or any part of the Collateral is made on credit or for future delivery, the Agent shall not be required to apply any portion of the sale price to the Obligations until such amount actually is received by the Agent, and any Collateral so sold may be retained by the Agent until the sale price is paid in full by the purchaser or purchasers thereof. The Secured Party shall not incur any liability in case any such purchaser or purchasers shall fail to pay for the Collateral so sold, and, in case of any such failure, the Collateral may be sold again.
- (g) <u>Disposition of Proceeds of Sale</u>. The proceeds resulting from the collection, liquidation, sale or other disposition of the Collateral shall be applied, <u>first</u>, to the reasonable costs and expenses (including reasonable attorneys' fees) of retaking, holding, storing, processing and preparing for sale, selling, collecting and liquidating the Collateral, and the like; <u>second</u>, to the satisfaction of all Obligations; and <u>third</u>, any surplus remaining after the satisfaction of all Obligations, provided no Commitment or Letter of Credit is outstanding, to be paid over to the Grantor or to whomsoever may be lawfully entitled to receive such surplus.
- (h) <u>Certain Waivers</u>. To the extent permitted by applicable law, the Grantor waives all claims, damages and demands against the Agent and the Lenders arising out of the repossession, retention or sale of the Collateral, or any part or parts thereof, except to the extent any such claims, damages and awards arise out of the gross negligence or willful misconduct of the Agent or the Lenders.
- (i) <u>Remedies Cumulative</u>. The rights and remedies provided under this Agreement are cumulative and may be exercised singly or concurrently, and are not exclusive of any other rights and remedies provided by law or equity.

20568574v3 - 22 -

- (j) <u>Deficiency</u>. If the proceeds of sale, collection or other realization of or upon the Collateral pursuant to this Section 16 are insufficient to cover the costs and expenses of such realization and the payment in full of the Obligations, the Grantor shall remain liable for any deficiency.
- Agent Appointed Attorney-in-Fact. The Grantor hereby irrevocably appoints the 17. Agent as the Grantor's attorney-in-fact, effective upon the occurrence and during the continuance of an Event of Default, with full authority in the place and stead of the Grantor, and in the name of the Grantor, or otherwise, from time to time, in the Agent's sole and absolute discretion to do any of the following acts or things: (a) to do all acts and things and to execute all documents necessary or advisable to perfect and continue perfected the security interests created by this Agreement and to preserve, maintain and protect the Collateral; (b) to do any and every act which the Grantor is obligated to do under this Agreement; (c) to prepare, sign, file and record, in the Grantor's name, any financing statement covering the Collateral; (d) to endorse and transfer the Collateral upon foreclosure by the Agent; (e) to grant or issue an exclusive or nonexclusive license under the Copyrights, the Patents or the Marks to anyone upon foreclosure by the Agent; (f) to assign, pledge, convey or otherwise transfer title in or dispose of the Copyrights, the Patents or the Marks to anyone upon foreclosure by the Agent; and (g) to file any claims or take any action or institute any proceedings which the Agent may reasonably deem necessary or desirable for the protection or enforcement of any of the rights of the Secured Party with respect to any of the Copyrights, the Patents and the Marks; provided, however, that the Agent shall be under no obligation whatsoever to take any of the foregoing actions, and neither the Agent nor the Secured Party shall have any liability or responsibility for any act or omission (other than the Agent's or the Secured Party's own gross negligence or willful misconduct) taken with respect thereto.
- 18. <u>Costs and Expenses</u>. The Grantor agrees to pay to the Agent all reasonable costs and out-of-pocket expenses (including reasonable attorneys' fees and disbursements) incurred by the Agent in the enforcement or attempted enforcement of this Agreement, whether or not an action is filed in connection therewith, and in connection with any waiver or amendment of any term or provision hereof. All reasonable advances, charges, costs and expenses, including reasonable attorneys' fees and disbursements, incurred or paid by the Agent in exercising any right, privilege, power or remedy conferred by this Agreement (including the right to perform any obligation of the Grantor), or in the enforcement or attempted enforcement thereof, shall be secured hereby and shall become a part of the Obligations and shall be due and payable to the Agent by the Grantor on demand therefor.
- 19. <u>Transfers and Other Liens</u>. The Grantor agrees that, except as specifically permitted under the Credit Agreement, it will not (i) sell, assign, exchange, lease, license, transfer or otherwise dispose of, or contract to sell, assign, exchange, transfer or otherwise dispose of, or grant any option with respect to, any of the Collateral, or (ii) create or permit to exist any Lien upon or with respect to any of the Collateral, and the Grantor acknowledges that the Secured Party does not authorize any of the foregoing.
- 20. <u>Understandings With Respect to Waivers and Consents</u>. The Grantor represents, warrants and agrees that each of the waivers and consents set forth herein are made with full knowledge of their significance and consequences, with the understanding that events giving rise

20568574v3 - 23 -

to any defense or right waived may diminish, destroy or otherwise adversely affect rights which the Grantor otherwise may have against any Secured Party or others, or against any Collateral. If any of the waivers or consents herein are determined to be unenforceable under applicable law, such waivers and consents shall be effective to the maximum extent permitted by law.

- 21. <u>Indemnity</u>. The Grantor hereby indemnifies the Agent and the Secured Party from and against any and all claims, losses and liabilities resulting from this Agreement (including enforcement of this Agreement), except to the extent such claims, losses or liabilities result from the Agent's or the Secured Party's gross negligence or willful misconduct.
- Amendments, Etc. No amendment or waiver of any provision of this Agreement nor consent to any departure by the Grantor herefrom (other than supplements to the Schedules hereto in accordance with the terms of this Agreement) shall in any event be effective unless the same shall be in writing and made in accordance with Section 9.1 of the Credit Agreement, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given. References to Schedules in this Agreement shall include all supplements to such Schedules delivered by the Grantor to the Agent in accordance with the terms of this Agreement.
- 23. <u>Notices</u>. All notices and other communications provided for hereunder shall be given in the manner, and to the respective addresses, set forth in Section 9.2 of the Credit Agreement.
- 24. Continuing Security Interest; Successors and Assigns. This Agreement shall create a continuing security interest in the Collateral and shall (i) remain in full force and effect until payment in full in cash of the Obligations (other than contingent indemnity obligations) and the termination or expiration of the Commitments, all Letters of Credit and any applicable bankruptcy preference period, (ii) be binding upon the Grantor, its successors and assigns and (iii) inure, together with the rights and remedies of the Agent hereunder, to the benefit of the Agent, and any successor Agent, for the benefit of the Secured Party and their respective successors and assigns, subject to the terms of the Credit Agreement. Subject to Section 9.6 of the Credit Agreement, any Lender may assign or otherwise transfer any Loans, Commitments, Letters of Credit or participations therein, or any rights in Collateral held by it to any other Person, and such other Person shall thereupon become vested with all the benefits in respect thereof granted to such Agent or Lender herein or otherwise. Nothing set forth herein or in any other Loan Document is intended or shall be construed to give to any other party any right, remedy or claim under, to or in respect of this Agreement or any other Loan Document or any Collateral. The Grantor's successors and assigns shall include, without limitation, a receiver, trustee or debtor-in-possession thereof or therefor, provided that, none of the rights or obligations of the Grantor hereunder may be assigned or otherwise transferred.
- 25. Release of Grantor. (a) This Agreement and all obligations of the Grantor hereunder and all security interests granted hereby shall be released and terminated when all Obligations have been paid in full in cash and when all Commitments, all Letters of Credit and any applicable bankruptcy preference period have expired. Upon such release and termination, all rights in and to the Collateral shall automatically revert to the Grantor, and the Agent and the Lenders shall return any Pledged Collateral in their possession to the Grantor, or to the Person or

20568574v3 - 24 -

Persons legally entitled thereto, and shall endorse, execute, deliver, record and file all instruments and documents, and do all other acts and things, reasonably required for the return of the Collateral to the Grantor, or to the Person or Persons legally entitled thereto, and to evidence or document the release of the interests of the Secured Party arising under this Agreement, all as reasonably requested by, and at the sole expense of, the Grantor.

- (b) The Agent agrees that if an Asset Disposition permitted under the Credit Agreement occurs with respect to any Collateral, the Agent shall release such Collateral that is the subject of such Asset Disposition to the Grantor free and clear of the Lien under this Agreement, provided that so long as any Obligations (other than contingent indemnity obligations) remain outstanding under the Credit Agreement or any Commitment or Letter of Credit remains outstanding, the Agent shall have no obligation to make such release until arrangements reasonably satisfactory to it have been made for delivery to it of any Net Proceeds of any Asset Disposition required to be used to prepay the Obligations (other than contingent indemnity obligations) pursuant to Section 2.5(b) of the Credit Agreement.
- 26. GOVERNING LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF CALIFORNIA WITHOUT REFERENCE TO ITS CHOICE OF LAW RULES.
- 27. <u>Counterparts</u>. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by telecopier shall be effective as delivery of a manually executed counterpart of this Agreement.

20568574v3 - 25 -

IN WITNESS WHEREOF, the Grantor has executed this Agreement by its duly authorized representative as of the date first written above.

**GRANTOR** 

N.V. PERRICONE LLC

Name: James L. O'Hara
Title: Vice President & Secretary

Security Agreement

# SCHEDULE A

### PLEDGED COLLATERAL

1. Pledged Shares

None

2. Pledged Partnership Interests

None

3. Pledged Limited Liability Company Interests

100% of the Borrower's right, title and interest in, to and under Royalties SPE, LLC, a Delaware limited liability company

Security Agreement CLI-1356691

#### **COPYRIGHTS, PATENTS AND MARKS**

#### **COPYRIGHTS**

None

#### PATENTS AND PATENT LICENSES

- 1. See Attached Annex 1
- 2. Patent License Agreement, dated May 25, 1999, between Johnson & Johnson Consumer Companies, Inc. and Nicholas V. Perricone, MD
- 3. License Agreement, dated March 27, 1995, between Nicholas V. Perricone, MD and Jan Marini Skin Research, Inc.
- 4. General License Agreement, dated May 1, 2002, between Nu Skin International, Inc. and Nicholas V. Perricone, MD, as amended by Amendment #1 to General License Agreement dated April 1, 2003.
- 5. License Agreement, dated August 8, 2003, between Jarrow Formulas, Inc. and Nicholas V. Perricone, MD.
- 6. License Agreement, dated September 10, 2003, between Nicholas V. Perricone, MD and Doctors' Preferred, Inc.
- 7. Technology Access Agreement, dated May 25, 1999, between Johnson & Johnson Consumer Companies, Inc., and Nicholas V. Perricone, MD

#### MARKS

1. See Attached Annex 2

Security Agreement CLI-1356691

# ANNEX I

See Attached

# ANNEX II

See Attached

St. Onge Steward Johnston Reens LLC

Page 1 of 23 Pages

Exhibit 4.12(d)

Run Date: 3/3/2006 11:51 AM

Selv Ma	holas \	Nicholas V. Perricone Trademarks  OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive 1*:	radem	larks		7 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) (			The second secon
***************************************	Total Control	extensional to a 1 to 2 to 1 to 1 to 1 to 1 to 1 to 1 to	and the second second second second second second second second second						deMakadaka Ar A T
CLIENT	MATTER	COUNTRY		The second of th	FILING	SEPTA! NO	ISSUE		EXPIRE
19600	T0061A	United States	Registered	NTP COMPLEX	1997/11/10	75/387,846	2000/02/08	2,315,317	2010/02/08
00961	T0063A	United States	Registered	N.V. PERRICONE, M.D. COSMECEUTICALS	1997/11/19	75/392,888	1999/04/06	2,237,822	2009/04/06
00961	T0063AAR	Argentina	Pending	N.V. PERRICONE, M.D.	2005/09/21	2,619,495		e de colonia de diferencia del conferencia del	And the state of t
00961	T0063AAU	Australia	Registered	N.V. PERRICONE, M.D. COSMECEUTICALS	2002/10/24	931890	2003/07/03	931890	2012/10/24
00961	T0063ABR1	Brazil	Published	N.V. PERRICONE, M.D. COSMECEUTICALS	2005/03/29	827274858			
00961	T0063ABR2	Brazil	Published	N.V. PERRICONE, M.D. COSMECEUTICALS	2005/03/29	827274866			
19600	T0063ABR3	Brazil	Published	N.V. PERRICONE, M.D. COSMECEUTICALS	2005/03/29	827274874			
00961	T0063ACA	Canada	Registered	N.V. PERRICONE, M.D. COSMECEUTICALS	2002/06/17	1,143,541	2004/03/09	TMA604,493	2019/03/09
00961	T0063ACN	China	Registered	N.V. PERRICONE, M.D. COSMECEUTICALS	2002/06/13	3,209,721	2004/03/06	3,209,721	2014/03/06
00961	T0063AEP	Europe	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2005/03/03	4330213	The state of the s		
00961	T0063AJP	Japan	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2005/03/14	2005-21856	A TOTAL OF THE TOT		
		ANAMATA IN THE CASE WHEN THE WHOLE WHEN THE WASHINGTON TO THE WHOLE WHEN THE WHOLE WHO				A. COLAR			

Run Date: 3/3/2006 11:51 AM

Exhibit 4.12(d)

Page 2 of 23 Pages

	Annohim at a 1 contraction and annohim of the state of th	NO DATE		The second secon		060 2013/01/15				772 2015/01/25		
es antiquadados (14 de 15 co 15 co 15 de 1	ISSIE	DATE REG NO	S I			2003/01/16 1029060				2005/01/25 2,920,772		
THE REAL PROPERTY AND PROPERTY	Names can can of the state of the first property of the case of th	SERIAL NO 40-2005-0047595	40-2005-0047594	705314	705398	91003077	359,910	2005-04026	2005-04027	78/341,288		06-11.070
Manhade de sero mane e e e e e e e e e e e e e e e e e e	FILING	<b>DATE</b> 2005/10/13	2005/10/13	2005/03/03	2004/03/03	2002/01/24	2002/02/02	2005/03/02	2005/03/02	2003/12/16	2006/02	2006/01/
We takken immerphotopytation of the control of the		N.V. PERRICONE, M.D.	N.V. PERRICONE, M.D. COSMECEUTICALS	N.V. PERRICONE, M.D. COSMECEUTICALS	N.V. PERRICONE, M.D. COSMECEUTICALS	N.V. PERRICONE, M.D. COSMECEUTICALS	N.V. PERRICONE, M.D. COSMECEUTICALS	N.V. PERRICONE, M.D. COSMECEUTICALS	N.V. PERRICONE, M.D. COSMECEUTICALS	N.V. PERRICONE, M.D. COSMECEUTICALS and Design	N.V. PERRICONE, M.D. COSMECEUTICALS	N.V. PERRICONE, M.D. COSMECEUTICALS
Indusive t*;		SIATUS Pending	Pending	Pending	Pending	Registered	Allowed	Pending	Pending	Registered	To Be Filed	Pending
OPEN MATTERS; CLIENIS: Inclusive 00961; MATTERS: Inclusive		South Korea	Korea	Mexico	Mexico	Taiwan	Uruguay	South Africa	South Africa	United States	United Arab Emitates	Colombia
tters; CLIENIS;	MATTED	T0063AKR	T0063AKR2	T0063AMX1	T0063AMX2	T0063ATW	T0063AUY	T0063AZA1	T0063AZA2	T0063B	T0063AAE	T0063ACO
OPEN MA	1341 C		00961	19600	19600	00961	00961	00961	19600	00961	00961	000961

St. Onge Steward Johnston Reens LLC

465793

Exhibit 4.12(d)

Page 3 of 23 Pages

COME, M.D. JUCALS         DATE DATE 2006/02         SERIAL NO         DATE DATE DATE DATE DATE DATE REG NO         REG NO           COME, M.D. JUCALS         2006/02         3005/2643         REG NO           COME, M.D. JUCALS         2006/02         3005/2643           COME, M.D. JUCALS         2006/02         2006/02           COME, M.D. JUCALS         2006/02         2006/02           COME, M.D. JUCALS         2006/02         305314           COME, M.D. JUCALS         2006/02/12         313,295           JUCONE, M.D. JUCALS         2006/02/13         305,398         2005/12/12           COONE, M.D. JUCALS         2006/02/13         305,398         2005/12/12         913,295           JUCONE, M.D. JUCALS         2006/02/13         305,398         2005/12/12         913,295           JUCONE, M.D. JUCALS         2006/02/13         305,398         2005/12/12         913,295	Ž	holas V	Nicholas V. Perricone T	Tradem	marks		a palantany, e y, e y			
TONGSJAKN   PORTOR   PORTOR   PORTOR   PORTOR   PORTOR	OPEN Ma	itters; CLIENTS:	Inclusive 00961; MATTERS: In	ndusive t*;	A COLUMN TO THE TOTAL OF THE TO	THE RESERVE OF THE PROPERTY OF				and an our proportional physical property or a function of the contract of the
TONGSAMCA   Carch Republic   To Be Filed IN V. PERRUCONE, M.D.   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02   2006/02	CLIENT	MATTER	TO THE STATE OF TH	CTATIC	NATIONAL MATERIAL CONTRACTOR CONT	FILING		ISSUE		EXPIRE
TO063MEG         Egypt         TO BE FINED         NV. PERRICONE, M.D.         2006/02           TO063MGR         Greece         TO BE FINED         COSMECEUTICALS         2006/02           TO063MH         Hong Kong         Pending         NV. PERRICONE, M.D.         2006/01/26         300572643           T0063MH         Hong Kong         Pending         NV. PERRICONE, M.D.         2006/01/26         300572643           T0063ML         Israel         TO BE Filed INV. PERRICONE, M.D.         2006/02         A006/02           T0063AN         Lisrael         TO BE Filed INV. PERRICONE, M.D.         2006/02         A006/02           T0063ANW         Kuwait         TO BE Filed INV. PERRICONE, M.D.         2006/02         A006/02           T0063ARW         Kuwait         TO Be Filed INV. PERRICONE, M.D.         2006/02         A006/02           T0063ARW         Makico         Pending         NV. PERRICONE, M.D.         2006/02           T0063ARW         Makico         Pending         NV. PERRICONE, M.D.         2006/02/02           T0063ARW         Poland         To File         NV. PERRICONE, M.D.         2006/02/02           T0063ARW         Rapistered         NV. PERRICONE, M.D.         2006/02/02           T006/02         COSMECEUTICALS	00961	T0063ACZ	Czech Republic	To Be Filed	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02	SERIAL NO	<b>DATE</b>	REG NO	DATE
TODGSAKR         Greece         TO BE Fled IN.Y. PERRICONE, M.D.         2006/02         2006/02           TODGSAHK         Hong Kong         Pending         IV.Y. PERRICONE, M.D.         2006/01/26         300572643           TODGSALL         Israel         TO BE Fled IN.Y. PERRICONE, M.D.         2006/02         2006/02           TODGSAND         Jondan         TO BE Fled IN.Y. PERRICONE, M.D.         2006/02         2006/02           TODGSANW         Kuwalt         TO BE Fled IN.Y. PERRICONE, M.D.         2006/02         2006/02           TODGSANW         Mexico         Pending         IV.Y. PERRICONE, M.D.         2006/02         2005/02/12/12           TODGSANX         Mexico         Registered IV.Y. PERRICONE, M.D.         2006/02/12/12         2005/02/12/12           TODGSARO         Romania         To Pile IN.Y. PERRICONE, M.D.         2006/02/12/12         2006/02/12/12           TODGSARO         Romania         To Pile IN.Y. PERRICONE, M.D.         2006/02/13         2006/02/12/12           TODGSARO         Romania         To De Filed IN.Y. PERRICONE, M.D.         2006/02/12/13         2006/02/13	00961	T0063AEG	Egypt	To Be Filed	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02	The state of the s			
TO063AHK         Hong Kong         Pending         IN.Y. PERRICONE, M.D.         2006/01/26         300572643           TO063ALL         Israel         To Be Filed IN.Y. PERRICONE, M.D.         2006/02         2006/02           TO063ALU         Jordan         To Be Filed IN.Y. PERRICONE, M.D.         2006/02         2006/02           TO063AKW         Kuwait         To Be Filed IN.Y. PERRICONE, M.D.         2006/02         2006/02           TO063AKW         Mexico         Pending IN.Y. PERRICONE, M.D.         2006/02         2005/12/12           TO063AWXZ         Mexico         Registered IN.Y. PERRICONE, M.D.         2006/03/03         705,398           TO063AWXZ         Mexico         Registered IN.Y. PERRICONE, M.D.         2006/02         2006/12/12           TO063ARV         NV. PERRICONE, M.D.         2006/02         2006/02           TO063ARV         NV. PERRICONE, M.D.         2006/02           TO06/02         SO06/02           TO06/02         SO06/02	00961	T0063AGR	Greece	To Be Filed	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02				
T0063AIL         Israel         TO Be Filed IN.Y. PERRICONE, M.D. COSWECEUTICALS         2006/02         2006/02           T0063AIV         Jordan         TO Be Filed IN.Y. PERRICONE, M.D. COSWECEUTICALS         2006/02         2006/02           T0063ARW         Kuwait         TO Be Filed IN.Y. PERRICONE, M.D. COSWECEUTICALS         2005/03/03         705314           T0063ARW         Mexico         Pending IN.Y. PERRICONE, M.D. COSWECEUTICALS         2006/02/2         913,295           T0063ARW         Poland         To File IN.Y. PERRICONE, M.D. COSWECEUTICALS         2006/02/2         2006/02/2           T0063ARO         Romania         To File IN.Y. PERRICONE, M.D. COSWECEUTICALS         2006/02/2         2006/02/2           T0063ARO         Romania         To File IN.Y. PERRICONE, M.D. COSWECEUTICALS         2006/02/13         2006/02/13           T0063ARO         Russia         Pending IN.Y. PERRICONE, M.D. COSWECEUTICALS         2006/02/13         2006/02/13	00961	T0063AHK	Hong Kong	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/01/26	300572643			
T0063A/V         Jordan         To Be Filed COSMECEUTICALS         N.V. PERRICONE, M.D.         2006/02           T0063AR/W         Kuwait         To Be Filed COSMECEUTICALS         2006/02         POSMECEUTICALS           T0063AR/X         Mexico         Pending COSMECEUTICALS         N.V. PERRICONE, M.D.         2005/03/03         705,398         2005/12/12         913,295           T0063AR/X         Mexico         Registered COSMECEUTICALS         N.V. PERRICONE, M.D.         2006/02/2         2006/02/2         PISSON           T0063AR/Q         Romania         To File COSMECEUTICALS         N.V. PERRICONE, M.D.         2006/02/2         PISSON         PISSON           T0063AR/Q         Romania         To Be Filed N.Y. PERRICONE, M.D.         2006/02/2         PISSON         PISSON	00961	T0063AIL	Israel	To Be Filed	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02				And the state of t
T0063AKW         Kuwait         To Be Filed COSMECEUTICALS         N.V. PERRICONE, M.D.         2006/02         2006/02           T0063AMX1         Mexico         Pending COSMECEUTICALS         N.V. PERRICONE, M.D.         2005/03/03         705,398         2005/12/12         913,295           T0063AMX2         Mexico         Registered COSMECEUTICALS         N.V. PERRICONE, M.D.         2006/02/2         2006/02/2         1706/06/2           T0063ARD         Romania         To Be Filed N.V. PERRICONE, M.D.         2006/02/2         2006/02/13         COSMECEUTICALS           T0063ARU         Russia         Pending N.V. PERRICONE, M.D.         2006/02/13         2006/02/13         ROSMECEUTICALS	00961	T0063AJO	Jordan		N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02		WITH THE COLOR OF		
T0063AMX1         Mexico         Pending         N.V. PERRICONE, M.D.         2005/03/03         705314           T0063AMX2         Mexico         Registered         N.V. PERRICONE, M.D.         2004/03/03         705,398         2005/12/12         913,295           T0063APL         Poland         To File         N.V. PERRICONE, M.D.         20006/02/7         2006/02/7           T0063ARO         Romania         To Be Filed         N.V. PERRICONE, M.D.         2006/02/13           T0063ARU         Russia         Pending         N.V. PERRICONE, M.D.         2006/02/13	00961	T0063AKW	Kuwait		N.V. PERRICONE, M.D. COSMECEUTICALS	2009/02				
T0063AMX2         Mexico         Registered COSMECEUTICALS         N.V. PERRICONE, M.D.         2004/03/03         705,398         2005/12/12         913,295           T0063APL         Poland         To File         N.V. PERRICONE, M.D.         2006/02/2         2006/02/2         2006/02/2           T0063ARO         Romania         To Be Filed COSMECEUTICALS         N.V. PERRICONE, M.D.         2006/02/13         COSMECEUTICALS           T0063ARU         Russia         Pending COSMECEUTICALS         N.V. PERRICONE, M.D.         2006/02/13         Russia	00961	T0063AMX1	Mexico	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2005/03/03	705314			
T0063APL Poland To File N.V. PERRICONE, M.D.  COSMECEUTICALS  T0063ARO Romania To Be Filed N.V. PERRICONE, M.D.  COSMECEUTICALS  T0063ARU Russia Pending N.V. PERRICONE, M.D.  COSMECEUTICALS	00961	T0063AMX2	Mexico	Registered	N.V. PERRICONE, M.D. COSMECEUTICALS	2004/03/03	705,398	2005/12/12	913,295	2015/03/03
T0063ARO Romania To Be Filed N.V. PERRICONE, M.D. COSMECEUTICALS T0063ARU Russia Pending N.V. PERRICONE, M.D. COSMECEUTICALS	00961	T0063APL	Poland	To File	N.V. PERRICONE, M.D. COSMECEUTICALS	20006/02/				
T0063ARU Russia Pending N.V. PERRICONE, M.D. COSMECEUTICALS	19600	T0063ARO	Romania		N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02				
	00961	T0063ARU	Russia	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02/13				

St. Onge Steward Johnston Reens LLC

Run	Run Date: 3/3/2006 11:51 AM	11:51 AM		Exhibit 4.12(d)				Page 4	Page 4 of 23 Pages
Z	holas V	Nicholas V. Perricone Trad	Fraden	emarks					a some deive return
OPEN M.	atters; CLIENTS:	OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*;	Inclusive – t*;	THE REAL PROPERTY OF THE PROPE	THE THE STATE OF T		PROPERTY OF THE PROPERTY OF TH	emolecularismentalista (mariema antare a no produce esta por de empresa de esta de empresa de esta	
CLIENT	election of a livery limit	COUNTRY	STATAS	A WWW.	FLING		ISSUE		EXPIRE
00961	00961 T0063ASA	Saudi Arabia	To Be Filed		2006/02	SEKIAL NO	DATE	REG NO	DATE
00961	T0063ATR	Turkey	To Be Filed	Filed N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02	* total a recognision and a state of the "Typ"   1 - 1 - 1 common			
00961	T0063C	United States	Pending	N.V. PERRICONE, M.D.	2006/01/26	78/799,850			
00961	T0063CAR	Argentina	To Be Filed	Filed N.V. PERRICONE, M.D.	2006/02				
00961	T0063CBM	Bermuda	To Be Filed	Filed N.V. PERRICONE, M.D.	2006/02			the control of the second seco	
00961	T0063CBR1	Brazil	To Be Filed	N.V. PERRICONE, M.D.	2006/02			THE PROPERTY OF THE PROPERTY O	
00961	T0063CBR2	Brazil	To Be Filed	Filed N.V. PERRICONE, M.D.	2006/02			To any other than the state of	
00961	T0063CBS	Bahamas	To Be Filed	Filed N.V. PERRICONE, M.D.	2006/02	a e . O copo de popo più minimo modo provinciare l'amendo di decembra mando			
00961	T0063CCA	Canada	To Be Filed	Filed N.V. PERRICONE, M.D.	2006/02				
00961	T0063CCL	Chile	To Be Filed	Filed N.V. PERRICONE, M.D.					**************************************
00961	T0063CCN	IR/China	Pending	N.V. PERRICONE, M.D.	2006/02/06	en colonia e de coloniamente e debajo en contra como como como como como como como com	· · · · · · · · · · · · · · · · · · ·		

Exhibit 4.12(d)

Page 5 of 23 Pages

)	7 7 7 7 7 7 7	The state of the s					*****	······································	
OPEN M	atters; CLIENTS;	OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*,	inclusive t*;	AND THE RESERVE OF THE PROPERTY OF THE PROPERT	the formation today (10.1 to 1.5.1 to 1	a the commence of the control of the			TO A THE COLUMN ASSESSMENT ASSESS
CLIENT	MATER A	COUNTRY OF COURSE AND	CTATION CONTRACTOR OF THE CONT	ACCOL TO A COLUMN A COMMENTAL MANAGEMENT OF THE COLUMN ASSESSMENT OF TH	E E E E E E E E E E E E E E E E E E E		ISSUE	. Fr. 1. et al. et a	EXPIRE
00961		Colombia	To Be Filed	N.V. PERRICONE, M.D.	2006/02	SERIAL NO	DATE	REG NO	DATE
00961	T0063CCR	Costa Rica	To Be Filed	N.V. PERRICONE, M.D.	2006/02				- P MATERIA ANDRE MA SUPLICE SUBSTITUTE STATES AND ADDRESS AND ADD
00961	T0063CID	Indonesia	To Be Filed	To Be Filed N.V. PERRICONE, M.D.	2006/02				
00961	T0063CIN	India	To Be Filed	To Be Filed N.V. PERRICONE, M.D.	2006/02				2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
00961	T0063CMX1	Mexico	To Be Filed	To Be Filed N.V. PERRICONE, M.D.	2006/02	***************************************	a nalistradu armenia menena a a tra de la agraza (manene menena de la composição de la composi de la composição de la composição de la composição de la composi		
00961	T0063CMX2	Mexico	To Be Filed	N.V. PERRICONE, M.D.					2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
00961	T0063CPA	Panama	To Be Filed	To Be Filed N.V. PERRICONE, M.D.	2006/02				
00961 00961	T0063CPE T0063CPH	Peru Philipines	To Be Filed To Be Filed	To Be Filed N.V. PERRICONE, M.D. To Be Filed N.V. PERRICONE, M.D.	2006/02				
00961	T0063CUY	Uruguay	To Be Filed	N.V. PERRICONE, M.D.	2006/02				
00961	T0063CVE	Venezuela	To Be Filed	N.V. PERRICONE, M.D.	2006/02				
00961	T0095ABR	Brazil	Registered	Dr. N.V. Perricone Cosmeceuticals	1999/08/04	821882619	2003/09/16	821882619	2013/09/16

St. Onge Steward Johnston Reens LLC

Exhibit 4.12(d)

Page 6 of 23 Pages

	ZADIOA	DATE	2017/07/26	2009/06/17	2010/10/27	2012/10/22	2014/04/13			2013/01/14	A PART OF THE PART	2013/09/16	
	~~~	REG NO	TMA565,310	1,224,146	4,427,244	2,640,234	2,832,268			2,674,550	manadad ministra e e e e e e e e e e e e e e e e e e e	2,765,243	
The second section of the second section is a second section of the	ISSUF	DATE	2002/07/26	2000/08/07	2000/10/27	2002/10/22	2004/04/13			2003/01/14		2003/09/16	And the state of t
	DELEVER MANUFACTORIS DEL ALLE = 1 QUELT LE ROUGE d'ATRACTE ANN REMARCE INDICE.	SERIAL NO	1,019,057	001224146	56199/1999	75/867,724	75/867,723	78652196	78/488,493	76/347,862	78/731,279	76/345,862	78652234
The state of the s	FILING	and and a second se	1999/06/15	1999/06/17	1999/06/25	1999/12/10	1999/12/10	2005/06/16	2004/09/23	2001/12/12	2005/10/12	. 2001/12/06	2005/06/16
	Months in microfield in communication commany arms of the Carles in microfield many transfer and the communication of the communication	NAME	Dr. N.V. Perricone Cosmeceuticals	Dr. N.V. Perricone Cosmeceuticals	Dr. N.V. Perricone Cosmeceuticals	THE WRINKLE CURE	THE WRINKLE CURE	THE WRINKLE CURE DIET	THE WRINKLE CURE	N.V. PERRICONE, M.D. NUTRICEUTICALS	THE WRINKLE CURE CLINIC	OUTPATIENT THERAPY	LAYERED REJUVENATION TECHNOLOGY
S: Indusive t*;		STATUS	Registered	Registered	Registered	Registered	Registered	Pending	Suspended	Registered	Pending	Registered	Pending
OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*;	The second of the second secon	WINDS	Canada	Europe	Japan	United States	United States	United States	United States	United States	United States	United States	United States
tters; CLIENTS:		CLIEBE MALER	IOUSSACA	T009SAEP	Т0095АЈР	T0105A	T0105B	T0134B	T0105C	T0150A	T0153B	T0155A	T0157B
OPEN Ma	1301		TOSON	00961	00961	00961	00961	00961	00961	00961	00961	00961	00961

St. Onge Steward Johnston Reens LLC

Exhibit 4.12(d)

Page 7 of 23 Pages

**EXPIRE DATE**2014/02/06 2015/05/17 2012/08/31 **REG NO** 3,209,720 2,952,811 1012501 2004/02/06 2005/05/17 2002/09/01 ISSUE DATE SERIAL NO 76/409,298 76/976,381 78/486,124 827362412 827351909 3,209,720 90033609 1,254,077 1050438 4636596 4636595 STATUS NAME
Registered PERRICONE (Chinese Characters) 2002/06/13 THE PERRICONE PRESCRIPTION 2002/05/20 Registered THE PERRICONE PRESCRIPTION 2002/05/20 Registered PERRICONE (Chinese Characters) 2001/08/14 THE PERRICONE PRESCRIPTION 2004/09/20 THE PERRICONE PRESCRIPTION 2005/04/12 THE PERRICONE PRESCRIPTION 2005/04/19 THE PERRICONE PRESCRIPTION 2005/04/19 THE PERRICONE PRESCRIPTION 2005/04/14 THE PERRICONE PRESCRIPTION 2005/04/30 THE PERRICONE PRESCRIPTION 2005/04/30 FILING DATE Nicholas V. Perricone Trademarks OPEN Matters; CLIENTS: Inclusive -- 00961; MATTERS: Inclusive -- t\*; Published **Published** Pending Pending Allowed Pending Pending Pending United States United States United States Country China Australia Taiwan Canada China Brazil Brazil T0167CBR2 T0167CCN2 T0164ACN T0164ATW T0167CAU T0167CBR T0167CCN T0167CCA CLIENT MATTER T0167A T0167C T0167B 00961 00961 00961 00961 00961 00961 00961 00961 00961 00961 00961

Exhibit 4.12(d)

Page 8 of 23 Pages

CLERY MATTER         COUNTRY         STATUS         NAME         FUND         FUND         PROPRIE         EXPRISE         PROPRIED	PEN Ma	tters; CLENTS:	OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*	raden Idusive t*;	marks		APT OF TAXABLE CONTRACT CONTRA	ACTIVE TO LINEARIZATION OF THE PARTY OF THE	The section of the se	
TOLISTICAN   CONTRICT   STATUS   NAME   CONTRICT   STATUS   NAME   CONTRICT   CONTRICT	FRAT					FLING		ISSIE	tes es d'Assistantes de la Maria de la de des mesentaciones commons de la composição de la	2/075
TO167CIP   Japan   Pending   THE PERRICONE PRESCRIPTION   2005/04/15   2005-36875   2005-36875   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15   2005/04/15	0961	T0167CEP	European Community	STATUS Pending	NAME THE PERICONE PRESCRIPTION 2	E act a design	<b>SERIAL NO</b> 4,402,673	DATE	REG NO	DATE
TO167CKR         South Korea         Pending         THE PERRICONE PRESCRIPTION         2005/04/13         40-2005-16135           T0167CMX         Mexico         Granted         THE PERRICONE PRESCRIPTION         2005/04/13         712,032         2005/06/28         889,282           T0167CMX         Mexico         Granted         THE PERRICONE PRESCRIPTION         2005/04/13         712,032         2005/06/28         889,283           T0167CLV         Talwan         Pending         THE PERRICONE PRESCRIPTION         2005/04/13         094017129         809,083           T0167CLV         Uniguay         Pending         THE PERRICONE PRESCRIPTION         2005/04/14         2005/0377         2005/0377           T0167CLXA         South Africa         Pending         THE PERRICONE PRESCRIPTION         2005/04/14         2005/0377           T0256AA         United States         Published         THE PERRICONE PROMISE         2005/04/14         1051018	1960	T0167CJP	Japan	Pending	THE PERRICONE PRESCRIPTION 2	2005/04/25	2005-36875			
TO167CMX	0961	T0167CKR	South Korea	Pending	THE PERRICONE PRESCRIPTION 2	2005/04/13	40-2005-16135			
TO167CMXZ         Mexico         Granted         THE PERRICONE PRESCRIPTION         2005/04/13         2005/06/28         889,283           T0167CTW         Taiwan         Pending         THE PERRICONE PRESCRIPTION         2005/04/13         094017129         889,283           T0167CLY         Uruguay         Pending         THE PERRICONE PRESCRIPTION         2005/05/31         362,672         8005/07376           T0167CZA         South Africa         Pending         THE PERRICONE PRESCRIPTION         2005/04/14         2005/07377           T0256A         United States         Published         THE PERRICONE PROMISE         2004/09/10         78/486,014           T0256AAU         Australia         Published         THE PERRICONE PROMISE         2005/04/15         1051018	1960	T0167CMX	Mexico	Granted	THE PERRICONE PRESCRIPTION 2	2005/04/13	712,032	2005/06/28	889,282	2015/04/13
T0167CTW         Taiwan         Pending         THE PERRICONE PRESCRIPTION         2005/04/13           T0167CUY         Uruguay         Pending         THE PERRICONE PRESCRIPTION         2005/05/31           T0167CZA         South Africa         Pending         THE PERRICONE PRESCRIPTION         2005/04/14           T0256A         United States         Published         THE PERRICONE PROMISE         2004/09/20           T0256AU         Australia         Published         THE PERRICONE PROMISE         2005/04/15	0961	T0167CMX2	Mexico	Granted	THE PERRICONE PRESCRIPTION 2	2005/04/13		2005/06/28	889,283	2015/04/13
Uruguay       Pending       THE PERRICONE PRESCRIPTION       2005/05/31         South Africa       Pending       THE PERRICONE PRESCRIPTION       2005/04/14         South Africa       Pending       THE PERRICONE PRESCRIPTION       2005/04/14         United States       Published       THE PERRICONE PROMISE       2004/09/20         Australia       Published       THE PERRICONE PROMISE       2005/04/15	00961	T0167CTW	Taiwan	Pending	THE PERRICONE PRESCRIPTION 2	2005/04/13	094017129			***************************************
T0167CZA         South Africa         Pending         THE PERRICONE PRESCRIPTION         2005/04/14           T0167CZA2         South Africa         Pending         THE PERRICONE PRESCRIPTION         2005/04/14           T0256A         United States         Published         THE PERRICONE PROMISE         2004/09/20           T0256AAU         Australia         Published         THE PERRICONE PROMISE         2005/04/15	0961	T0167CUY	Uruguay	Pending	THE PERRICONE PRESCRIPTION 2	2005/05/31	362.672			
T0167CZA2 South Africa Pending THE PERRICONE PRESCRIPTION 2005/04/14 T0256A United States Published THE PERRICONE PROMISE 2004/09/20 T0256AAU Australia Published THE PERRICONE PROMISE 2005/04/15	0961	T0167CZA	South Africa	Pending	THE PERRICONE PRESCRIPTION 2	2005/04/14	2005/07376		and the second s	
T0256A United States Published THE PERRICONE PROMISE 2004/09/20 T0256AAU Australia Published THE PERRICONE PROMISE 2005/04/15	0961	T0167CZA2	South Africa	Pending	THE PERRICONE PRESCRIPTION 2	2005/04/14	2005/07377		· · · · · · · · · · · · · · · · · · ·	
T0256AAU Australia Published THE PERRICONE PROMISE 2005/04/15	1961	T0256A	United States	Published		2004/09/20	78/486,014		MATERIAL STATE AND STATE STATE STATE STATES AND STATES	
	1961	T0256AAU	Australia	Published		2005/04/15	1051018	And of the control of		

U
Ñ
٠.
च
Ò

Page 9 of 23 Pages

OPSES IN MARTERS; LICHENTS; Includence — 1-7-1         Park Marters; CLIENTS; Includence — 1-7-1         Park Marters; CLIENTS; Includence — 1-7-1         Park Marters; CLIENTS; Includence — 1-7-1         Park Marters; CLIENTS         Park Mark Mark         Park Mark Mark Mark         Park Mark Mark Mark         Park Mark Mark Mark Mark Mark Mark Mark M	S	holas V	Nicholas V. Perricone Trademarks	radem	larks	T T VALORAGE WAY.				
THE FORMULE   Pending   THE PERRUCONE PROMISE   2005/04/15   1,254,224   Pending   THE PERRUCONE PROMISE   2005/04/15   1,254,224   Pending   THE PERRUCONE PROMISE   2005/04/15   1,254,224   Pending   THE PERRUCONE PROMISE   2005/04/15   2,005-0016569   Pending   THE PERRUCONE PROMISE   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/08/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/08/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/04/15   2,005/	DEN M	itters; CLIENTS:	Indusive 00961; MATTERS: 1	ndusive - t*;				The state of the s		A COLON CONTRACTOR OF THE CONT
T0256ABR         Brazil         Pariding THE PERRUCONE PROMISE         2005/04/15         SERIAL NO         DATE         REG NO           T0256ACA         Canada         Pending         THE PERRUCONE PROMISE         2005/04/15         1,254,224         REG NO           T0256ACA         China         Pending         THE PERRUCONE PROMISE         2005/04/15         4,406,179         REG NO           T0256AP         Japan         Pending         THE PERRUCONE PROMISE         2005/04/15         40-2005-0016569         REG NO           T0256AF         South Korea         Pending         THE PERRUCONE PROMISE         2005/04/15         712539         REG NO           T0256AF         Tourise         Pending         THE PERRUCONE PROMISE         2005/04/15         712539         REG NO           T0256AF         Tourise         Pending         THE PERRUCONE PROMISE         2005/04/15         362.673         REG NO           T0256AF         South Africa         Pending         THE PERRUCONE PROMISE         2005/04/15         2005/04/15           T0256AF         Junked States         Pending         THE PERRUCONE PROMISE         2005/04/15         2005/04/15           T0256AF         Junked States         Pending         THE PERRUCONE PROMISE         2005/04/15         <	LIENT	MATTER	COINTE VIEW CONTRACTOR		AT TAN AT STATE AND A SECOND S	FILING		ISSUE		EXPIRE
T0256ACA         Canada         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ACN         China         Pending         THE PERRICONE PROMISE         2005/04/18           T0256ALP         Lurope         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ALP         Japan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ANY         Mexico         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ANY         Taiwan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ALW         Taiwan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ALW         Uruguay         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26           T0258AA         United States         Pending         THE PERRICONE PROMISE         2005/04/26	0961	T0256ABR	Brazil	Pending	NAME THE PERRICONE PROMISE	<b>DATE</b> 2005/05/25	<b>SERIAL NO</b> 827358318	DATE	REG NO	DATE
T0256ACM         China         Pending         THE PERRICONE PROMISE         2005/04/18           T0256AEP         Europe         Pending         THE PERRICONE PROMISE         2005/04/18           T0256AIP         Japan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AIM         Mexico         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AIW         Talwan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AIW         Uruguay         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26	00961	T0256ACA	Canada	Pending	THE PERRICONE PROMISE	2005/04/15	1,254,224			
T0256AEP         Europe         Pending         THE PERRICONE PROMISE         2005/04/18           T0256AJP         Japan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AKR         South Korea         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AWX         Mexico         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ATW         Taiwan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26           T0258AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26           T0258AZ         United States         Published         THE BRAIN-BEAUTY         2004/10/08	00961	T0256ACN	China	Pending	THE PERRICONE PROMISE	2005/04/30	4636597			
T0256AJP         Japan         Pending         THE PERRICONE PROMISE         2005/04/25           T0256AKR         South Korea         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AMX         Mexico         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ATW         Taiwan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ALW         Uruguay         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/16           T0256AZA         South Africa         Pending         THE BRAIN-BEAUTY         2004/10/00	00961	T0256AEP	Europe	Pending	THE PERRICONE PROMISE	2005/04/18	4,406,179			
T0256AKR         South Korea         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AMX         Mexico         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ATW         Taiwan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AUY         Uruguay         Pending         THE PERRICONE PROMISE         2005/04/16           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26           T0258A         United States         Published         THE BRAIN-BEAUTY         2004/10/08	00961	T0256AJP	Japan	Pending	THE PERRICONE PROMISE	2005/04/25	2005-36876			
T0256AMX         Mexico         Pending         THE PERRICONE PROMISE         2005/04/15           T0256ATW         Taiwan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AUY         Uruguay         Pending         THE PERRICONE PROMISE         2005/05/31           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26           T0258A         United States         Published         THE BRAIN-BEAUTY         2004/10/08	00961	T0256AKR	South Korea	Pending	THE PERRICONE PROMISE	2005/04/15	40-2005-0016569			7.4
T0256ATW         Talwan         Pending         THE PERRICONE PROMISE         2005/04/15           T0256AUY         Uruguay         Pending         THE PERRICONE PROMISE         2005/05/31           T0256AZA         South Africa         Pending         THE PERRICONE PROMISE         2005/04/26           T0258A         United States         Published         THE BRAIN-BEAUTY         2004/10/08	00961	T0256AMX	Mexico	Pending	THE PERRICONE PROMISE	2005/04/15	712539			
T0256AUY     Uruguay     Pending     THE PERRICONE PROMISE     2005/05/31       T0256AZA     South Africa     Pending     THE PERRICONE PROMISE     2005/04/26       T0258A     United States     Published     THE BRAIN-BEAUTY     2004/10/08	00961	Т0256АТW	Taiwan	Pending	THE PERRICONE PROMISE	2005/04/15	094017793		) Command of the comm	
T0256AZA South Africa Pending THE PERRICONE PROMISE 2005/04/26  T0258A United States Published THE BRAIN-BEAUTY 2004/10/08	00961	T0256AUY	Uruguay	Pending	THE PERRICONE PROMISE	2005/05/31	362.673			
T0258A United States Published THE BRAIN-BEAUTY 2004/10/08	1960	T0256AZA	South Africa	Pending	THE PERRICONE PROMISE	2005/04/26	2005/08349		**************************************	
	0961	T0258A	United States	Published	THE BRAIN-BEAUTY CONNECTION	2004/10/08	78/496,884			

e J/2/COU 11:21 AlY	Page 10 of 23 Pages
West Andready American Control of	

Nic	holas \	Nicholas V. Perricone Trademarks	raden	larks					
OPEN Ma	tters; CLIENTS:	OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*;	iclusive t*;	AND THE TAX OF THE TAX					AAA SEAMSTAN JA T F., US; 19'45 19'45 AAAA AAAAA SEE SAASAA
C TENT	KATTED				FILING	en e	ISSUE		EXPIRE
00061	Onosi Tologaca	manyone of the contrast of the	STATUS		DATE	SERIAL NO	DATE	REG NO	DATE
7000	PORCETOI	Calidud	Kegistered	SKIN & TOTAL BODY	2003/01/28	1,165,824	2004/07/15	TMA614,961	2019/07/15
00961	T0199AEP	European Community	Registered	SKIN & TOTAL BODY	2003/01/30	3038619	2004/12/21	3038619	2013/01/30
19600	T0199B	United States	Registered	SKIN & TOTAL BODY	2004/01/22	78/355,647	2005/03/22	2,935,651	2015/03/22
19600	T0199BAU	Australia	Registered	SKIN & TOTAL BODY	2004/07/13	1010991	2004/12/06	1010991	2014/07/13
19600	T0199BBR	Brazil	Published	SKIN & TOTAL BODY	2004/07/20	826713726		TO A TO A MATERIAL PROPERTY OF THE PROPERTY OF	
00961	T0199BCA	Canada	Allowed	SKIN & TOTAL BODY	2004/07/13	1,223,299			
00961	T0199BCN	China	Pending	SKIN & TOTAL BODY	2004/08/06	4208185			
19600	T0199BEP	Europe	Published	SKIN & TOTAL BODY	2004/07/15	3,944,501			
00961	Т0199ВЈР	Japan	Registered	SKIN & TOTAL BODY	2004/07/20	2004-66758	2005/02/18	4840108	2015/02/18
00961	T0199BKR	South Korea	Pending	SKIN & TOTAL BODY	2004/07/13	2004/31808	V. 144 ( Fr. 1, 1, 1), 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,		
00961	T01998MX	Mexico	Registered	SKIN & TOTAL BODY	2004/07/15	666803	2005/02/23	868161	2014/07/15

Dange	2
of 23	
č	5
Ξ	4
Pane	2

Exhibit 4.12(d)

Run Date: 3/3/2006 11:51 AM

OPEN ME	<b>NOIAS V</b>	NICHOIAS V. Perricone Trade OPEN MATTERS: Inclusive	raden	emarks *-		and the second s	AF	e e e e e e e e e e e e e e e e e e e	
		tentahaldikintolomoromoromoromoromoromata in anticolomica			nas vivas ano soci			agency of a size of	a salamatan
CLIENT	CLIENT MATTER	COUNTRY	STATUS	NAME	FIES	VI V	ISSUE		EXPIRE
00961	T0199BTW	Taiwan	Registered	SKIN & TOTAL BODY	2004/07/13	093032460	2005/04/16	1,147,896	2015/04/15
00961	T0199BZA	Africa	Pending	SKIN & TOTAL BODY	2004/07/13	2004/11726			
00961	T0200A	United States	Allowed	N.V. PERRICONE, M.D. THERAPEUTICS	2002/10/21	76/460,820			
00961	T0200ACA	Canada	Allowed	N.V. PERRICONE, M.D. THERAPEUTICS	2003/01/27	1,165,593			
00961	T0200ACN	China	Pending	N.V. PERRICONE, M.D. THERAPEUTICS	2003/02/28	3470566			
00961	T0200AEP	European Community	Registered	N.V. PERRICONE, M.D. THERAPEUTICS	2003/01/30	3038643	2005/01/17	3038643	2013/01/30
00961	T0200AJP	Japan	Registered	N.V. PERRICONE, M.D. THERAPEUTICS	2003/02/24	2003-13895	2004/08/13	4,794,994	2014/08/13
00961	T0200AKR	South Korea	Registered	N.V. PERRICONE, M.D. THERAPEUTICS	2003/01/30	2003-4445	2004/08/24	591085	2014/08/24
00961	T0200B	United States	Allowed	N.V. PERRICONE, M.D. THERAPEUTICS and Design	2003/12/16	78/341,291			1 man ( ) man
00961	T0200C	United States	Pending	N.V. PERRICONE, M.D. THERAPEUTICS	2005/08/11	78/690,438			
00961	T0203A	United States	Allowed	ELECTRIC-STIM	2003/02/11	78/213,497	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
	Mark Supplement								

Exhibit 4.12(d)

Page 12 of 23 Pages

CLIENT MATTER         COUNTRY         STRATUS         MANE         FULL NOT         FULL NOT         FULL NOT         FULL NOT         EXCRAÇA HOR         DATE         REG NO         DATE         DATE<	NEW WE	nolas V	NICHOIAS V. Perricone Tradel OPEN MATTERS: Inclusive t*,	radem dusive – t*;	marks	consider to the content of the conte	The state of the s	Addin Male and A.	ODDOORDISTANS I STANIE EERANGAA BELANGEROOMO	
TOZOGARR   Brazil   Pending   FLECTRUC-STIM GLOVE   Z003/03/13   78/214,331   DATE   REG NO.	THE REAL PROPERTY OF THE PARTY		A colorente de mentement de la citate de 1975 (se con colorente de mente de constructo en constructo	***************************************		The state of the s	THE THE SECTION SECTIO	de la America de la Constantina del Constantina de la Constantina		no distribution de la specie del
10206AR   United States	LIENT	MATTER	COUNTRY	STATUS	NANF	FILING	TO THE OWNER OF THE PARTY OF TH	ISSUE		EXPIRE
TOZOGAMER         Brazil         Pending         ELECTRIC-STIM GLOVE         2003/08/12         825758289           TOZOGACA         Canadda         Pending         ELECTRIC-STIM GLOVE         2003/07/21         1,183,757         2005/01/31         3317377           TOZOGAUP         Japan         Registered         ELECTRIC-STIM GLOVE         2003/08/13         3317377         2005/01/31         3317377           TOZOGAMR         South Korea         Registered         ELECTRIC-STIM GLOVE         2004/03/05         2003-63383         2004/04/30         4,768,561           TOZHAAA         United States         Published         NEUROPEPTIDE FACTAL         2004/01/22         78/355,532         2005/01/14         605891           TOZHAAAB         Brazil         Published         NEUROPEPTIDE FACTAL         2004/07/15         1011348         2005/01/13         1011348           TOZHAACA         Canadda         Pending         NEUROPEPTIDE FACTAL         2004/07/15         1,223,691         2005/01/13         1011348           TOZHAACA         Canadda         Pending         NEUROPEPTIDE FACTAL         2004/07/15         1,223,691         2005/01/13         1011348	10961	T0206A	United States	Allowed	ELECTRIC-STIM GLOVE	2003/02/13	78/214,351	DAIE	REG NO	DATE
T0206ACA         Canada         Pending         ELECTRIC-STIM GLOVE         2003/07/21         1,183,757         2005/01/31         3317377           T0206ALP         Europe         Registered         ELECTRIC-STIM GLOVE         2003/08/13         3317377         2005/01/31         3317377           T0206ALP         Japan         Registered         ELECTRIC-STIM GLOVE         2004/03/05         2003-63383         2004/04/30         4,768,561           T0206ALP         South Korea         Registered         ELECTRIC-STIM GLOVE         2004/03/05         2003-63790         2005/01/14         605891           T0244AA         United States         Published         NEUROPEPTIDE FACIAL         2004/01/22         78/355,532         2005/01/13         1011348           T0244AAB         Australia         Registered         NEUROPEPTIDE FACIAL         2004/07/15         1011348         2005/01/13         1011348           T0244AAB         Brazil         Published         NEUROPEPTIDE FACIAL         2004/07/15         1,223,691         2005/01/13         1011348           T0244ACN         Canada         Pending         NEUROPEPTIDE FACIAL         2004/07/15         1,223,691         2005/01/13         1011348	10961	T0206ABR	Brazil	Pending	ELECTRIC-STIM GLOVE	2003/08/12	825758289			
T0206AEP	0961	T0206ACA	Canada	Pending	ELECTRIC-STIM GLOVE	2003/07/21	1,183,757			
T0206AJP         Japan         Registered         ELECTRIC-STIM GLOVE         2004/03/OS         2003-63383         2004/04/30         4,768,561           T0206AKR         South Korea         Registered         ELECTRIC-STIM GLOVE         2003/08/11         2003-35790         2005/01/14         605891           T0244AA         United States         Published         NEUROPEPTIDE FACIAL         2004/01/22         78/355,532         2005/01/13         1011348           T0244AAU         Australia         Registered         NEUROPEPTIDE FACIAL         2004/07/15         1011348         2005/01/13         1011348           T0244ACA         Canada         Pending         NEUROPEPTIDE FACIAL         2004/07/15         1,223,691         2005/01/13         1011348           T0244ACA         Canada         Pending         NEUROPEPTIDE FACIAL         2004/07/15         1,223,691         2005/01/13         1011348           T0244ACA         China         Pending         NEUROPEPTIDE FACIAL         2004/07/15         1,223,691         2005/01/13         1011348	1960	T0206AEP	Europe	Registered	ELECTRIC-STIM GLOVE	2003/08/13	3317377	2005/01/31	3317377	2013/08/13
T0206AKR         South Korea         Registered         ELECTRIC-STIM GLOVE         2003/08/11         2003-35790         2005/01/14         605891           T0244A         United States         Published CONFORMER         NEUROPEPTIDE FACIAL CONFORMER         2004/07/15         78/355,532         78/355,532         1011348           T0244AAU         Australia         Registered CONFORMER         NEUROPEPTIDE FACIAL CONFORMER         2004/07/15         1011348         2005/01/13         1011348           T0244ACA         Canada         Pending CONFORMER         NEUROPEPTIDE FACIAL CONFORMER         2004/07/15         1,223,691         2004/07/15         1,223,691           T0244ACN         China         Pending CONFORMER         NEUROPEPTIDE FACIAL CONFORMER         2004/07/15         1,223,691         2004/07/15         1,223,691	1960	T0206AJP	Japan	Registered	ELECTRIC-STIM GLOVE	2004/03/05	2003-63383	2004/04/30	4,768,561	2014/04/30
T0244A         United States         Published CONFORMER         NEUROPEPTIDE FACIAL         2004/01/12         78/355,532         1011348         1011348           T0244AAU         Australia         Registered CONFORMER         NEUROPEPTIDE FACIAL CONFORMER         2004/07/15         1011348         2005/01/13         1011348           T0244AEA         Brazil         Published CONFORMER         NEUROPEPTIDE FACIAL CONFORMER         2004/07/15         1,223,691         CONFORMER           T0244ACA         China         Pending CONFORMER         NEUROPEPTIDE FACIAL CONFORMER         2004/07/15         1,223,691         CONFORMER	0961	T0206AKR	South Korea	Registered	ELECTRIC-STIM GLOVE	2003/08/11	2003-35790	2005/01/14	605891	2015/01/14
T0244AAU         Australia         Registered         NEUROPEPTIDE FACIAL         2004/07/15         1011348         2005/01/13         1011348           T0244ABR         Brazil         Published         NEUROPEPTIDE FACIAL         2004/07/20         826713734         1011348         1011348           T0244ACA         Canada         Pending         NEUROPEPTIDE FACIAL         2004/07/15         1,223,691         CONFORMER           T0244ACN         China         Pending         NEUROPEPTIDE FACIAL         2004/08/06         4208188	0961	T0244A	United States	Published	NEUROPEPTIDE FACIAL CONFORMER	2004/01/22	78/355,532			
T0244ABR         Brazil         Published         NEUROPEPTIDE FACIAL         2004/07/20           T0244ACA         Canada         Pending         NEUROPEPTIDE FACIAL         2004/07/15           T0244ACN         China         Pending         NEUROPEPTIDE FACIAL         2004/08/06           T0244ACN         China         Pending         CONFORMER         2004/08/06	1960	T0244AAU	Australia	Registered	NEUROPEPTIDE FACIAL CONFORMER	2004/07/15	1011348	2005/01/13	1011348	2014/07/15
T0244ACA Canada Pending NEUROPEPTIDE FACIAL 2004/07/15 CONFORMER T0244ACN China Pending NEUROPEPTIDE FACIAL 2004/08/06 CONFORMER	0961	T0244ABR	Brazil	Published	NEUROPEPTIDE FACIAL CONFORMER	2004/07/20	826713734			
T0244ACN China Pending NEUROPEPTIDE FACIAL 2004/08/06 CONFORMER	1960	T0244ACA	Canada	Pending	NEUROPEPTIDE FACIAL CONFORMER	2004/07/15	1,223,691			
	0961	T0244ACN	China	Pending	NEUROPEPTIDE FACIAL CONFORMER	2004/08/06	4208188		THE PROPERTY OF THE PROPERTY O	

St. Onge Steward Johnston Reens LLC

Page 13 of 23 Pages Exhibit 4.12(d)

Z	holas V	Nicholas V. Perricone Trademarks	radem	larks					
OPEN M	atters; CLIENTS:	OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*;	nclusive t*;	verifically interface a total of a country o		THE CONTRACT OF THE CONTRACT O	that about a local policy of the second seco	Office and the state of the sta	
CLIENT	MATTED	TOTAL STATE OF THE PROPERTY OF		e mandam manamangangan et a tê ê sama (ap a an doma ha doma ha para (ap a 16 a a e e e e e e e e e e e e e e e A doma ha mandam de e e e e e e e e e e e e e e e e e e	FILING		ISSUE	to major holdeddiadd Mareidd (1817 f. 1. c. 1. N <sub>1.2</sub> t. N <sub>2.2</sub> t. N <sub>3.2</sub> t. Specifical) ar (1. t. 1.	EXPIRE
00061	TONAMEN		SIAICS	KAME	DATE	SERIAL NO	DATE	REG NO	DATE
10600	10244AEF	edobe	Published	NEUROPEPTIDE FACIAL CONFORMER	2004/07/19	3951936			
00961	Т0244АЈР	Japan	Registered	NEUROPEPTIDE FACIAL CONFORMER	2004/07/20	2004-66759	2005/02/18	4840109	2015/02/18
00961	T0244AKR	South Korea	Pending	NEUROPEPTIDE FACIAL CONFORMER	2004/07/16	2004-32578			
19600	T0244AMX	Mexico	Pending	NEUROPEPTIDE FACIAL CONFORMER	2004/07/15	666,802			
00961	T0244ATW	Taiwan	Registered	NEUROPEPTIDE FACIAL CONFORMER	2004/07/16	093032924	2005/05/01	1150282	2015/04/30
00961	T0244AZA	South Africa	Pending	NEUROPEPTIDE FACIAL CONFORMER	2004/07/15	2004-11923			
00961	T0245ABR	Brazil	Published	NEUROPEPTIDE CONTOUR CREAM	2004/07/20	826713742			
00961	T0273ABR	Brasil	Published	NEUROPEPTIDE FACIAL CONTOUR	2005/11/04	827916450			
000961	T0245ACA	Canada	Pending	NEUROPEPTIDE CONTOUR CREAM	2004/07/16	1,223,830			
19600	T0245ACN	China	Pending	NEUROPEPTIDE CONTOUR CREAM	2004/08/06	4208187		e e d'ar d'ar l'Al te ambie mendichina annona ten statutura	
00961	T0245AJP	Japan	Registered	NEUROPEPTIDE CONTOUR CREAM	2004/07/20	2004-066760	2005/06/10	4871437	2015/06/10

Exhibit 4.12(d)

Run Date: 3/3/2006 11:51 AM

Page 14 of 23 Pages

	FYDIBE	DATE		2014/07/19	2015/03/15	2014/07/22	2015/11/25		2015/09/06		The state of the s		2015/06/10
		REG NO		868,165	1143392		542.269		2,993,474				4871438
	ISSUE	DATE		2005/02/23	2005/03/16	7 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2005/11/25		2005/09/06	I the manufacture of the state			2005/06/10
	edi Addi e e e e e e e e e e e e e e e e e e	SERIAL NO	2004-32579	667,391	093033153	2004/12399	59728/2005	2005/08186	78/355,542	826713750	1,223,829	4208186	2004-66761
	add to be seen a page of the seen of the s	DATE	/16	2004/07/19	2004/07/16	2004/07/22	2005/11/22	2005/11/01	2004/01/22	2004/07/20	2004/07/16	2004/08/06	2004/07/20
arks		NASE CONTRACTOR CONTRA	NEUROPEPTIDE CONTOUR CREAM	NEUROPEPTIDE CONTOUR CREAM	NEUROPEPTIDE CONTOUR CREAM	NEUROPEPTIDE CONTOUR CREAM	NEUROPEPTIDE FACIAL CONTOUR	NEUROPEPTIDE FACIAL CONTOUR	NEUROPEPTIDE FACIAL SERUM PREP	NEUROPEPTIDE FACIAL SERUM PREP	NEUROPEPTIDE FACIAL SERUM PREP	NEUROPEPTIDE FACIAL SERUM PREP	NEUROPEPTIDE FACIAL SERUM PREP
radem		1	Pending	Registered	Registered	Pending	Registered	Pending	Registered	Published	Pending	Pending	Registered
Nicholas V. Perricone Trademarks  OPEN Matters, CLENTS: Inclusive 00961; MATTERS: Inclusive t*;	emiden en e	SOUR TRANSPORTED AND A STATE OF THE PROPERTY O	South Korea	Mexico	Taiwan	South Africa	Switzerland	Sweden	United States	Brazil	Canada	China	Japan
Tolas V ters; CLIENTS: I		Standard Spin		T0245AMX	T0245ATW	T0245AZA	Т0273АСН	T0273ASE	T0246A	T0246ABR	T0246ACA	T0246ACN	T0246AJP
OPEN MAI	1	!		00961	19600	00961	00961	19600	00961	00961	19600	19600	19600

Pages
$\approx$
ಹ
55
Page

Exhibit 4.12(d)

Run Date: 3/3/2006 11:51 AM

FILING   SERIAL NO   DATE   REG NO	Z	holas V	Nicholas V. Perricone Trademarks	radem	larks	from \$100 miles for free from				
MANTER   COUNTRY   Pending   Pendi	OPEN ME	atters; CLIENTS:	Inclusive 00961; MATTERS: I	nclusive t*;				a a a a a a a a a a a a a a a a a a a	manahamintan in danah intanah atau atau atau atau atau atau atau at	1
TO246ARV	CI TCMT	7	destricts to the country of decrease among because and a to the transport of the second of the secon			FILING	Parameter and the second secon	ISSUE	The same of the sa	EXPIRE
10246APK	כרובויי	MALIEK	COUNTRY	STATUS	AAK	DATE	SERIAL NO	DATE	REG NO	DATE
T0246AVX	00961	10246AKR	South Korea	Pending	NEUROPEPTIDE FACIAL SERUM PREP	2004/07/16	2004-32580			
T0246ATW         Talwan         Registered PREP         NEUROPEPTIDE FACIAL SERUM         2004/07/16         093033155         2005/05/01         1150286           T0246AZA         South Africa         Pending         NEUROPEPTIDE FACIAL SERUM         2004/10/14         73/499,773         10525/A           T0257AAU         United States         Pending         NEUROPEPTIDE EYE AREA         2004/10/14         78/499,773         1058946           T0257AAU         Australia         Pending         NEUROPEPTIDE EYE AREA         2005/06/06         1,260,279         1,260,279           T0257ACA         Canada         Pending         NEUROPEPTIDE EYE AREA         2005/06/08         1,260,279         1,260,279           T0257ACA         China         Pending         NEUROPEPTIDE EYE AREA         2005/06/08         1,260,279           T0257ACP         China         Pending         NEUROPEPTIDE EYE AREA         2005/06/06         1,260,279           T0257ALP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/013         2005/06/13	19600	T0246AMX	Mexico	Registered	NEUROPEPTIDE FACIAL SERUM PREP	2004/07/19	667,392	2005/02/23	868166	2014/07/19
T0246AZA         South Africa         Pending         NEUROPEPTIDE FACIAL SERUM         2004/10/14           T0257A         United States         Pending         NEUROPEPTIDE EYE AREA         2004/10/14           T0257AAU         Australia         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257ACA         Canada         Pending         NEUROPEPTIDE EYE AREA         2005/06/08           T0257ACA         Canada         Pending         NEUROPEPTIDE EYE AREA         2005/06/08           T0257ACA         China         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257ACB         Europe         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257ALP         Europe         Pending         NEUROPEPTIDE EYE AREA         2005/06/07           T0257ALP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/07           T0257AJP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/07	00961	T0246ATW	Talwan	Registered	NEUROPEPTIDE FACIAL SERUM PREP	2004/07/16	093033155	2005/05/01	1150286	2015/04/30
T0257A         United States         Pending         NEUROPEPTIDE EYE AREA         2004/10/14           T0257AAU         Australia         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257AAU         Australia         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257ACA         Canada         Pending         NEUROPEPTIDE EYE AREA         2005/06/08           T0257ACN         China         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257AEP         Europe         Pending         NEUROPEPTIDE EYE AREA         2005/06/07           T0257AEP         Europe         Pending         NEUROPEPTIDE EYE AREA         2005/06/07           T0257AEP         Bapan         Pending         NEUROPEPTIDE EYE AREA         2005/06/07           T0257ABP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/03	00961	T0246AZA	South Africa	Pending	NEUROPEPTIDE FACIAL SERUM PREP	2004/07/16	2004-12010			
T0257AAU         Australia         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257ABR         Brazil         Published         NEUROPEPTIDE EYE AREA         2005/04/13           T0257ACA         Canada         Pending         NEUROPEPTIDE EYE AREA         2005/06/08           T0257ACN         China         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257AEP         Europe         Pending         NEUROPEPTIDE EYE AREA         2005/06/07           T0257AJP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/13           T0257AJP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/13	00961	T0257A	United States	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2004/10/14	78/499,773			
T0257ABR         Brazil         Published         NEUROPEPTIDE         EYE AREA         2005/04/13           T0257ACA         Canada         Pending         NEUROPEPTIDE         EYE AREA         2005/06/08           T0257ACN         China         Pending         NEUROPEPTIDE         EYE AREA         2005/06/06           T0257AEP         Europe         Pending         NEUROPEPTIDE         EYE AREA         2005/06/07           T0257AJP         Japan         Pending         NEUROPEPTIDE         EYE AREA         2005/06/13           T0257AJP         Japan         Pending         NEUROPEPTIDE         EYE AREA         2005/06/13	00961	T0257AAU	Australia	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/06	1058846			
T0257ACA         Canada         Pending         NEUROPEPTIDE EYE AREA         2005/06/08           T0257ACN         China         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257AEP         Europe         Pending         NEUROPEPTIDE EYE AREA         2005/06/07           T0257AJP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/13           T0257AJP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/13	00961	T0257ABR	Brazil	Published	NEUROPEPTIDE EYE AREA CONTOUR	2005/04/13	M161267			
T0257ACN         China         Pending         NEUROPEPTIDE EYE AREA         2005/06/06           T0257AEP         Europe         Pending         NEUROPEPTIDE EYE AREA         2005/06/07           T0257AJP         Japan         Pending         NEUROPEPTIDE EYE AREA         2005/06/13           CONTOUR         CONTOUR         CONTOUR         CONTOUR	00961	T0257ACA	Canada	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/08	1,260,279	to the same and th		
T0257AEP Europe Pending NEUROPEPTIDE EYE AREA 2005/06/07 CONTOUR T0257AJP Japan Pending NEUROPEPTIDE EYE AREA 2005/06/13 CONTOUR	00961	T0257ACN	China	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/06	THE PROPERTY OF THE PROPERTY O	TO CALL TO THE REAL PROPERTY OF THE PARTY OF		
T0257AJP Japan Pending NEUROPEPTIDE EYE AREA 2005/06/13 CONTOUR	00961	T0257AEP	Europe	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/07	4491288			
	00961	T0257AJP	Japan	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/13	2005-52651			

Exhibit 4.12(d)

Page 16 of 23 Pages

MATTER   COUNTRY   MAME   Pending   CONTOUR   Pending   Pending	Z		Nicholas V. Perricone Trade	radem	marks		The special sp			
T MATTER         COUNTRY         STATUS         MAKE         FILING         SEGIAL NO         ASSUE           10.025/AR/R         KORE9         Pending         NEUROPETIDE EYE AREA         2005/06/07         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782         2005-23782	OPEN Ma	atters; CLIENTS:	Inclusive 00961; MATTERS: In	clusive t*;	CHICAGO I AND TANDES AND A CANADA AND A CANA	The state of the s		and the second s	**************************************	
TO257AMY   Mexico   Pending   CONTOUR   TO257AMY   Mexico   Pending   CONTOUR   TO257AMY   Mexico   Pending   CONTOUR   TO257AMY   Mexico   Pending   CONTOUR   TO257AMY   Talwan   Pending   Pend						FILING		TSSIIF	More To the Anna Anna Anna Anna Anna Anna Anna Ann	20106
10.257AMX	ברדנות.		Sea obligable (committee objects) and an experimental series of a figure and an examination of the form of the objects of the	STATUS	Today promises the contribute of the contribute	DATE	SERIAL NO	DATE	PFG NO	DATE
TO257AUY	19600			Pending		2005/06/07	2005-25782	Section 1		ACCOUNTY TO A STATE OF THE ACCOUNTY OF THE ACC
T0257ATW         Taiwan         Pending         NEUROPEPTIDE EYE AREA         2005/06/17         363.274           T0257AZA         South Africa         Pending         NEUROPEPTIDE EYE AREA         2005/06/17         363.274           T0257AZA         South Africa         Pending         NEUROPEPTIDE EYE AREA         2005/06/17         363.274           T0259AAU         United States         Published         THE THREE-DAY NUTRITIONAL         2004/10/08         78/496,9S8           T0259AAU         Australia         Registered         THE THREE-DAY NUTRITIONAL         2005/01/14         1,037/8S8         2005/06/08           T0259ACA         Canada         THE THREE-DAY NUTRITIONAL         2005/03/22         827211813         Augustalia           T0259ACA         Canada         THE THREE-DAY NUTRITIONAL         2005/03/25         4,514,575           T0259ACA         Canada         Pending         THE THREE-DAY NUTRITIONAL         2005/03/25         4,514,507           T0259ACA         China         Pending         THE THREE-DAY NUTRITIONAL         2005/03/25         4,514,507	00961	T0257AMX	Mexico	Registered	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/07	721,645	The state of the s	895,794	
T0257AUY         Unaguay         Pending         NEUROPEPTIDE EYE AREA         2005/06/17         363.274           T0257AZA         South Africa         Pending         NEUROPEPTIDE EYE AREA         2005/06/10         2005/11112           T0259AA         United States         Published         THE THREE-DAY NUTRITIONAL         2004/10/08         78/496,9S8           T0259AAU         Australia         Registered         THE THREE-DAY NUTRITIONAL         2005/01/14         1,037,8S8         2005/06/08           T0259ACA         Canada         Pending         THE THREE-DAY NUTRITIONAL         2005/03/02         827211813         FACE-LIFT           T0259ACN         China         Pending         THE THREE-DAY NUTRITIONAL         2005/02/25         4,514,507           T0259AEP         Europe         Published         THE THREE-DAY NUTRITIONAL         2005/02/25         4,514,507	00961	T0257ATW	Taiwan	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/06	094026721		***	
T0257AZA   South Africa   Pending   NEUROPEPTIDE EYE AREA   2005/06/06   2005/11112	00961	T0257AUY	Uruguay	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/17	363.274		The state of the s	
T0259A         United States         Published FACE-LIFT         THE THREE-DAY NUTRITIONAL         2004/10/08         78/496,958           T0259AAU         Australia         Registered THE THREE-DAY NUTRITIONAL         2005/01/14         1,037,858         2005/06/08           T0259ABR         Brazil         Published THE THREE-DAY NUTRITIONAL         2005/03/02         827211813         E005/06/08           T0259ACA         Canada         Pending THE THREE-DAY NUTRITIONAL         2005/01/24         1,244,575         E005/01/24           T0259ACN         China         Pending THE THREE-DAY NUTRITIONAL         2005/01/24         4,514,507         E005/01/27           T0259AEP         Europe         Published THE THREE-DAY NUTRITIONAL         2005/01/17         4243135	00961	T0257AZA	South Africa	Pending	NEUROPEPTIDE EYE AREA CONTOUR	2005/06/06	2005/11112		control of the state of the sta	
T0259AAU         Australia         Registered         THE THREE-DAY NUTRITIONAL         2005/01/14         1,037,858         2005/06/08           T0259ABR         Brazil         Published         THE THREE-DAY NUTRITIONAL         2005/03/02         827211813         2005/06/08           T0259ACA         Canada         Pending         THE THREE-DAY NUTRITIONAL         2005/01/24         1,244,575           T0259ACN         China         Pending         THE THREE-DAY NUTRITIONAL         2005/02/25         4,514,507           T0259ACN         Europe         Published         THE THREE-DAY NUTRITIONAL         2005/01/17         4243135	00961	T0259A	United States	Published		2004/10/08	78/496,958	PROPERTY PROPERTY OF THE PROPE		
T0259ABR         Brazil         Published         THE THREE-DAY NUTRITIONAL         2005/03/02           T0259ACA         Canada         Pending         THE THREE-DAY NUTRITIONAL         2005/01/24           T0259ACN         China         Pending         THE THREE-DAY NUTRITIONAL         2005/02/25           T0259AEP         Europe         Published         THE THREE-DAY NUTRITIONAL         2005/01/17           T0259AEP         Europe         Published         THE THREE-DAY NUTRITIONAL         2005/01/17	00961	T0259AAU	Australia	Registered	E-DAY NUTRITIONAL	2005/01/14	1,037,858	2005/06/08	1,037,858	2015/01/14
T0259ACA         Canada         Pending         THE THREE-DAY NUTRITIONAL         2005/01/24           T0259ACN         China         Pending         THE THREE-DAY NUTRITIONAL         2005/02/25           T0259AEP         Europe         Published         THE THREE-DAY NUTRITIONAL         2005/01/17	00961	T0259ABR	Brazil	Published		2005/03/02	827211813	* Charles and the Company of Comp		
T0259ACN China Pending THE THREE-DAY NUTRITIONAL 2005/02/25 FACE-LIFT T0259AEP Europe Published THE THREE-DAY NUTRITIONAL 2005/01/17 FACE-LIFT	00961	T0259ACA	Canada	Pending	E-DAY NUTRITIONAL	2005/01/24	1,244,575			7 / · · · · · · · · · · · · · · · · · ·
T0259AEP Europe Published THE THREE-DAY NUTRITIONAL 2005/01/17 FACE-LIFT	00961	T0259ACN	China	Pending		2005/02/25	4,514,507			With William Publishers of the Association (Association)
	00961	T0259AEP	Europe	Published	E-DAY NUTRITIONAL	2005/01/17	4243135			

St. Onge Steward Johnston Reens LLC

Exhibit 4.12(d)

Page 17 of 23 Pages

OPEN MATRIES: Locusive - 00961; MATTERS: Inclusive - 1+;         NAME         FILTING         SERIAL NO           CLIENT         MATE         THE THREE-DAY NUTRITIONAL         2005/03/14         2005-1857           00961         T0259A/D         Japan         Pending         PET THREE-DAY NUTRITIONAL         2005/01/14         2005-1857           00961         T0259A/D         Talwan         Pending         PET THREE-DAY NUTRITIONAL         2005/01/14         2005-1857           00961         T0259A/D         Talwan         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14         09402112           00961         T0259A/D         Talwan         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14         0050/01/14 <th>The Control of the Co</th> <th>AND AND THE RESIDENCE AND ADDRESS OF THE PERSON NAMED AND ADDR</th> <th></th> <th>_</th> <th></th> <th></th> <th></th> <th></th>	The Control of the Co	AND AND THE RESIDENCE AND ADDRESS OF THE PERSON NAMED AND ADDR		_				
In MATTER         COUNTRY         STATUS         NAME         FILLING           T0259AIP         Japan         Pending         THE THREE-DAY NUTRITIONAL         2005/03/14           T0259AKR         South Korea         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259AWX         Mexico         Registered         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259ATW         Taiwan         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259AZA         South Africa         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0253AAU         United States         Suspended         FACE-LIFT         2005/01/14           T0263ABR         Brazil         Pending         FACE FIRMING ACTIVATOR         2005/06/02           T0263ACA         Canada         Pending         FACE FIRMING ACTIVATOR         2005/06/02           T0263ACA         China         Pending         FACE FIRMING ACTIVATOR         2005/05/27	fatters; CLIENTS: Indusi	ve 00961; MATTERS: Inclusive -	— CART	ACCURATE LIVE AND	A Control of the communication with the control of the control of the communication of the control of the contr	100 C C C C C C C C C C C C C C C C C C	A state of the office and the Add Proportional Proportion	er i er
MANUEL   LANGE   DATE	No. of the last of	e de la descripción de la construcción de la constr		FILING	eden in annotation (1811) (1814) (1814) (1814) (1814) (1814) (1814) (1814) (1814) (1814) (1814) (1814) (1814)	11.004	Tropical Residentifications among appear (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984), (1984	
10259A/N		e menempera de grappos destablis desdebbases i a 193 e. e. p. de constituir amagine proprie			SERIAL NO	DATE		EXPIRE
T0259AKR         South Korea         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259ATW         Taiwan         Registered         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259ATW         Taiwan         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259AZA         South Africa         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0263AA         United States         Suspended         FACE-LIFT         2005/01/14           T0263AB         Brazil         Pending         FACE FIRMING ACTIVATOR         2005/05/27           T0263ACA         Canada         Pending         FACE FIRMING ACTIVATOR         2005/05/27           T0263ACN         China         Pending         FACE FIRMING ACTIVATOR         2005/05/27				†	2005-21857	The same of the sa		WIE
T0259AWX         Mexico         Registered FACE-LIFT         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259ATW         Taiwan         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259AZA         South Africa         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0263A         United States         Suspended         FACE-LIFT         2005/01/14           T0263ABW         Australia         Pending         FACE FIRMING ACTIVATOR         2005/05/27           T0263ACA         Canada         Pending         FACE FIRMING ACTIVATOR         2005/05/27           T0263ACN         China         Pending         FACE FIRMING ACTIVATOR         2005/05/27		The state of the s	1		2005-1854			A PARTICULAR DE LA CALLANDA DE LA CA
T0259ATW         Taiwan         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0259AZA         South Africa         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0263AA         United States         Suspended         FACE-LIFT         2004/12/02           T0263ABB         Brazil         Pending         FACE FIRMING ACTIVATOR         2005/06/02           T0263ACA         Canada         Pending         FACE FIRMING ACTIVATOR         2005/06/02           T0263ACN         China         Pending         FACE FIRMING ACTIVATOR         2005/06/02	T0259AMX		-		0697023	2005/05/13	881465	2005/01/14
T0259AZA         South Africa         Pending         THE THREE-DAY NUTRITIONAL         2005/01/14           T0263A         United States         Suspended         FACE FIRMING ACTIVATOR         2004/12/02           T0263AAU         Australia         Pending         FACE FIRMING ACTIVATOR         2005/05/27           T0263ACA         Canada         Pending         FACE FIRMING ACTIVATOR         2005/06/02           T0263ACN         China         Pending         FACE FIRMING ACTIVATOR         2005/05/27	T0259ATW				094002112			
T0263A         United States         Suspended FACE FIRMING ACTTVATOR         2004/12/02           T0263AAU         Australia         Pending         FACE FIRMING ACTTVATOR         2005/05/27           T0263ABR         Brazil         Published         FACE FIRMING ACTTVATOR         2005/06/02           T0263ACA         Canada         Pending         FACE FIRMING ACTTVATOR         2005/05/27           T0263ACN         China         Pending         FACE FIRMING ACTTVATOR         2005/05/27			***************************************		2005/00720			
T0263AAU         Australia         Pending         FACE FIRMING ACTIVATOR         2005/05/27           T0263ABR         Brazil         Published         FACE FIRMING ACTIVATOR         2005/06/02           T0263ACA         Canada         Pending         FACE FIRMING ACTIVATOR         2005/05/27           T0263ACN         China         Pending         FACE FIRMING ACTIVATOR         2005/05/27	-1 / br / be disposed page	THE RESIDENCE AND ADDRESS OF THE AND ADDRESS OF THE		2004/12/02	78/526,255	:		enterprise application and account of the color of the co
T0263ABR         Brazil         Published         FACE FIRMING ACTIVATOR         2005/06/02           T0263ACA         Canada         Pending         FACE FIRMING ACTIVATOR         2005/05/27           T0263ACN         China         Pending         FACE FIRMING ACTIVATOR         2005/05/27	T0263AAU			2005/05/27	1057621			
T0263ACA Canada Pending FACE FIRMING ACTIVATOR 2005/05/27 T0263ACN China Pending FACE FIRMING ACTIVATOR 2005/05/27			· vintrin s · marginarantem m commission con s	2005/06/02	827468903			
T0263ACN China Pending FACE FIRMING ACTIVATOR 2005/05/27				2005/05/27	1259148			
				2005/05/27	4684196			medicate de la composition della composition del
00961 T0263AEP Europe Pending FACE FIRMING ACTIVATOR 2005/06/01 004476875	T0263AEP Europ			2005/06/01	004476875			A COPING TO THE WINDOWS COME CONTRACT C

Exhibit 4.12(d)

Page 18 of 23 Pages

IING ACTIVATOR IING ACTIVATOR IING ACTIVATOR IING ACTIVATOR TIDE FACIAL TIDE FACIAL TIDE FACIAL	ZICU.	olas v	Nicholas V. Perricone Trademarks	radem	arks					
MATTER         COUNTRY         STATUS         NAME           T0263AJP         Japan         Pending         FACE FIRMING ACTIVATOR           T0263AMX         Mexico         Pending         FACE FIRMING ACTIVATOR           T0263AJW         Tawian         Pending         FACE FIRMING ACTIVATOR           T0263AZA         South Africa         Pending         FACE FIRMING ACTIVATOR           T0273AB         United States         Pending         FACE FIRMING ACTIVATOR           T0273ABB         Brasil         T0 Be Filed NEUROPEPTIDE FACIAL           T0273ACA         Canada         Pending         NEUROPEPTIDE FACIAL           CONTOUR         CONTOUR         CONTOUR           T0273ACH         Switzerland         Pending         NEUROPEPTIDE FACIAL           T0273ACH         Switzerland         To Be Filed CONTOUR           T0273ACH         Switzerland         To Be Filed CONTOUR	PEN Matter	s; CLIENTS:	Inclusive 00961; MATTERS: Inc	clusive t*;	evinente de la	to the state of th	*** ) ) (* dade) i je rovejskod midozbijskima namazi oz i s a a a a a a a a a a a a a a a a a a	TO THE CONTRACT OF THE CONTRAC	There is a few transport and an analysis of the second and an analysis of the second and the sec	
T0263AP         Japan         Pending         FACE FIRMING ACTIVATOR           T0263AMX         Mexico         Pending         FACE FIRMING ACTIVATOR           T0263AWX         Mexico         Pending         FACE FIRMING ACTIVATOR           T0263AVY         Turguay         Pending         FACE FIRMING ACTIVATOR           T0263AV         United States         Pending         FACE FIRMING ACTIVATOR           T0273A         United States         Pending         FACE FIRMING ACTIVATOR           T0273ABR         Brasil         To Be Filed         NEUROPEPTIDE FACIAL           T0273ACA         Canada         Pending         NEUROPEPTIDE FACIAL           T0273ACH         Switzerland         Pending         NEUROPEPTIDE FACIAL           T0273ACH         Switzerland         To Be Filed NEUROPEPTIDE FACIAL           T0273ACH         Switzerland         To Be Filed NEUROPEPTIDE FACIAL	YENT		economica de estados estados estados estados en estados en estados en estados en entre en estados en entre esta		A COMMANDA (IN AND A COMMAND COMMAND COMMAND AND AND AND AND AND AND AND AND AND	FILING	e managanie die des frances et l' · · · · · · · · · · · · · · · · · ·	ISSUE		EXPIRE
T0263AWY Korea Pending FACE FIRMING ACTIVATOR T0263AWY Tawian Pending FACE FIRMING ACTIVATOR T0263AUY Uruguay Pending FACE FIRMING ACTIVATOR T0263AZA South Africa Pending FACE FIRMING ACTIVATOR T0273ABR Brasil To Be Filed NEUROPEPTIDE FACIAL CONTOUR T0273ACA Canada Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACA Canada Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland To Be Filed NEUROPEPTIDE FACIAL CONTOUR		45 1ER	enderson enterson enterson in the contract of	i		DATE	SERIAL NO	DATE	REG NO	DATE
T0263AKR Korea Pending FACE FIRMING ACTIVATOR T0263AWX Mexico Pending FACE FIRMING ACTIVATOR T0263AVY Uruguay Pending FACE FIRMING ACTIVATOR T0263AZA South Africa Pending FACE FIRMING ACTIVATOR T0273A United States Pending CONTOUR T0273ACA Canada To Be Filed NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland To Be Filed NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland To Be Filed NEUROPEPTIDE FACIAL CONTOUR		ZosAJP		Michaelma, ad and March Second, also be alleged	FACE FIRMING ACTIVATOR	2005/06/02	2005-49238		Territoria managaman and and and and and and and and and a	
T0263AMX Mexico Pending FACE FIRMING ACTIVATOR T0263ATW Tawian Pending FACE FIRMING ACTIVATOR T0263AZA South Africa Pending FACE FIRMING ACTIVATOR T0273A United States Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACA Canada Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland To Be Filed CONTOUR CONTOUR	**************************************	1263AKR			FACE FIRMING ACTIVATOR	2005/05/27	2005-24324		mondamediname of a series - 1-12 - 1-12 - 11-14 to Annual Series - 1-12 - 12-14 to Annual Series	
T0263AUY Uruguay Pending FACE FIRMING ACTIVATOR T0263AZA South Africa Pending FACE FIRMING ACTIVATOR T0273A United States Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACA Canada T0 Be Filed NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland T0 Be Filed NEUROPEPTIDE FACIAL CONTOUR CONTOUR CONTOUR CONTOUR CONTOUR CONTOUR CONTOUR	delite menteral management	263AMX	Mexico		FACE FIRMING ACTIVATOR	2005/05/26	719742		and control of the co	
T0263AUY Uruguay Pending FACE FIRMING ACTIVATOR T0263AZA South Africa Pending FACE FIRMING ACTIVATOR T0273A United States Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACA Canada Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland To Be Filed NEUROPEPTIDE FACIAL CONTOUR CONTOUR CONTOUR CONTOUR		263ATW			FACE FIRMING ACTIVATOR	2005/05/27	094025383		delimentaria i i i apparativa i a se	
T0263AZA     South Africa     Pending     FACE FIRMING ACTIVATOR       T0273A     United States     Pending     NEUROPEPTIDE FACIAL       T0273ABR     Brasil     To Be Filed     NEUROPEPTIDE FACIAL       T0273ACA     Canada     Pending     NEUROPEPTIDE FACIAL       T0273ACH     Switzerland     To Be Filed     NEUROPEPTIDE FACIAL       T0273ACH     Switzerland     To Be Filed     NEUROPEPTIDE FACIAL       CONTOUR     CONTOUR	<u> </u>	263AUY			FACE FIRMING ACTIVATOR	2005/06/28	362.674			
T0273A United States Pending NEUROPEPTIDE FACIAL CONTOUR T0273ABR Brasil To Be Filed NEUROPEPTIDE FACIAL CONTOUR T0273ACA Canada Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland To Be Filed CONTOUR CONTOUR	The second second second second second second	263AZA			FACE FIRMING ACTIVATOR	2005/06/01	2005/10802			
T0273ABR Brasil To Be Filed NEUROPEPTIDE FACIAL CONTOUR T0273ACA Canada Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland To Be Filed CONTOUR CONTOUR		273A			NEUROPEPTIDE FACIAL CONTOUR	2005/04/04	78/601,148			To the state of th
T0273ACA Canada Pending NEUROPEPTIDE FACIAL CONTOUR T0273ACH Switzerland To Be Filed NEUROPEPTIDE FACIAL CONTOUR		273ABR	Brasil		NEUROPEPTIDE FACIAL CONTOUR					VITANA A DA TIA TIANTAN MANAGAMAN ANAMAN
T0273ACH Switzerland To Be Filed	<u> </u>	273ACA			NEUROPEPTIDE FACIAL SONTOUR	2005/10/31	1,277,718			
		273ACH	Switzerland		NEUROPEPTIDE FACIAL CONTOUR		Married N.A. Supplementary from the control of the			
00961 T0273ACN China Pending NEUROPEPTIDE FACIAL 200		273ACN	China	To a control of the c	NEUROPEPTIDE FACIAL SONTOUR	2005/10/31				

St. Onge Steward Johnston Reens LLC

Exhibit 4.12(d)

Page 19 of 23 Pages

2015/10/31 EXPIRE DATE REG NO ISSUE DATE 40-2005-0050726 2005-103993 05 3389180 SERIAL NO 094052667 2405648 0748108 FILING DATE 2005/10/31 2005/10/28 2005/11/01 2005/11/07 2005/11/01 2005/10/31 2005/10/31 2005/10/31 2005/ NEUROPEPTIDE FACIAL CONTOUR NEUROPEPTIDE FACIAL NEUROPEPTIDE FACIAL CONTOUR NEUROPEPTIDE FACIAL CONTOUR To Be Filed NEUROPEPTIDE FACIAL CONTOUR To Be Filed NEUROPEPTIDE FACIAL CONTOUR NEUROPEPTIDE FACIAL CONTOUR Nicholas V. Perricone Trademarks CONTOUR NAME OPEN Matters; CLIENTS: Inclusive -- 00961; MATTERS: Inclusive -- t\*; STATUS Pending Pending Pending Pending Pending Pending Pending Pending Pending South Africa **COUNTRY** Germany Denmark England Sweden France Mexico Taiwan Japan Korea Italy **CLIENT MATTER** 00961 T0273ADE T0273ADK T0273ATW T0273AGB T0273AKR T0273AMX T0273AFR T0273ASE T0273AZA T0273AIT T0273AJP 00961 00961 00961 19600 00961 00961 00961 00961 00961 00961

Exhibit 4.12(d)

Page 20 of 23 Pages

EXPIRE DATE REG NO ISSUE DATE **SERTAL NO** 2005/08186 78/711,979 1275608 745163 出 ĸ K K K 2 FILING DATE 2005/11/01 2005/09/13 2005/10/14 2005/10/25 2005/10/14 N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design NEUROPEPTIDE FACIAL Nicholas V. Perricone Trademarks CONTOUR NAME OPEN Matters; CLIENTS: Inclusive -- 00961; MATTERS: Inclusive -- t\*; **STATUS**Pending Pending Pending Pending Pending IR/European Community IR/South Korea IR/Switzerland United States IR/Australia COUNTRY Sweden IR/Japan IR/China Canada Mexico Brazil T0281ACH T0281AAU T0281ACA T0281AMX T0273ASE T0281ABR T0281ACN T0281AEP **T0281AKR** T0281AJP CLIENT MATTER T0281A 00961 00961 00961 00961 00961 00961 00961 00961 00961 00961 00961

St. Onge Steward Johnston Reens LLC

Pages
23
u
ਠ
****
~
Page

Exhibit 4.12(d)

Run Date: 3/3/2006 11:51 AM

CLIENT MATTERS   COUNTRY   CLIENTS Industries   CLIENT MATTERS   COUNTRY   CLIENT MATTERS   COUNTRY   CLIENT MATTERS   CLIE	Z Z	holas V	Nicholas V. Perricone Trademarks	aden.	larks					an f difficult parts
Pending         STATUS         MAME         DATE         REG NO           10281ANY2         Mexico         Pending         NV. PERRICONE, M.D. MENS         2005/10/14         745164         REG NO           10281ASS         Mexico         Pending         NV. PERRICONE, M.D. MENS         RR         RR           10281ASS         RA/Singapore         SCAIN FITNESS and Design         IR         RR           10281AIVY         Talwan         Pending         NV. PERRICONE, M.D. MENS         2005/10/18           10281AWO         International Registration         Pending         NV. PERRICONE, M.D. MENS         2005/10/14         2005/2061           10281AZA         South Africa         Pending         NV. PERRICONE, M.D. MENS         2005/10/14         2005/2061           10281AZA         South Africa         Pending         NV. PERRICONE, M.D. MENS         2005/10/14         2005/2062           10281AZA         South Africa         Pending         NV. PERRICONE, M.D. MENS         2005/10/14         2005/2062           10281AZA         South Africa         Pending         NV. PERRICONE, M.D. MENS         2006/10/16         78/785/748           10284A         United States         Pending         NV. PERRICONE, M.D. MENS         2006/10/16         78/785/748	OPEN M	itters; CLIENTS:	Inclusive 00961; MATTERS: Inc	lusive t*;	American and an analysis of the second secon	en umbilde ji umbilde distri kin da karanga sa na nagananan umpik ngin		e refere i e i 100 di v sobres brazioni apparandonimi de esti	NV AND ALL ALL AND	a company of the comp
TO281ARVO	CITENT	12 A TTTEO	a belak matanamangan mangan dipidahan atah dalam da 190 pilong terbahan da 190 pilong terbahan da 190 pilong t	The state of the s		(0	e e e e e e e e e e e e e e e e e e e	ISSUE	del confederatories des feres larcon d'assessant es se es per qu'a plus diferents des const	EXPIRE
TOZB14RU		MAI JEK	A 164 DECEMBER OF THE STATE OF	STATUS	ZXX		SERIAL NO	DATE	REG NO	DATE
T0281ARU         IR/Russia         N.Y. PERRICONE, M.D. MEN'S           T0281ASG         IR/Singapore         N.Y. PERRICONE, M.D. MEN'S           T0281ATW         Taiwan         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/18           T0281AUY         Uruguay         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/18           T0281AWO         International Registration         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZA         South Africa         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZAZ         South Africa         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZAZ         South Africa         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281B         United States         Pending         N.Y. PERRICONE, M.D. MEN'S         2006/01/05           T0284A         United States         Pending         MOIST LIPS         2006/01/05           T0285A         United States         Pending         NUTRIENT FACE FORTIFIER         2006/01/05	19600	10281AMX2		Pending	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design	10/14	745164	abedatasa et al. a.	modelma i e i e a a a a a a a a a a a a a a a	A THE STATE OF THE
T0281ASG         IR/Singapore         N.Y. PERRICONE, M.D. MEN'S         2005/10/18           T0281ATW         Taiwan         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/18           T0281AUY         Uruguay         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/18           T0281AWO         International Registration         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZA         South Africa         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281BZA         South Africa         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281BAZA         South Africa         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281B         United States         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0284A         United States         Pending         N.Y. PERRICONE, M.D. MEN'S         2006/01/05           T0285A         United States         Pending         N.Y. PERRICONE, M.D. MEN'S         2006/01/05	00961	T0281ARU	IR/Russia	menter and the state of the sta	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design		IR			
T0281ATW         Taiwan         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/18           T0281AUY         Uruguay         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/10           T0281AWO         International Registration         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/18           T0281AZA         South Africa         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZA2         South Africa         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZA2         South Africa         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/14           T0281B         United States         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/16           T0284A         United States         Pending         MOIST LIPS         2006/01/05           T0285A         United States         Pending         MUTRIENT FACE FORTIFIER         2006/01/05	00961	T0281ASG	IR/Singapore	Complete For State Continues in page 1995 (Fig. 7) - 1	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design		IR			
T0281AUY         Uruguay         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/20           T0281AWO         International Registration         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/18           T0281AZA         South Africa         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZA2         South Africa         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/14           T0281BB         United States         Pending         N.Y. PERRICONE, M.D. MEN'S         2005/10/16           T0284A         United States         Pending         MOIST LIPS         2006/01/05           T0285A         United States         Pending         MUTRIENT FACE FORTIFIER         2006/01/05	00961	T0281ATW		Pending	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design	2005/10/18	094050076	The state of the s		
T0281AWO         International Registration         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/18           T0281AZA         South Africa         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZA2         South Africa         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/14           T0281B         United States         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/05           T0284A         United States         Pending         MOIST LIPS         2006/01/05           T0285A         United States         Pending         NUTRIENT FACE FORTIFIER         2006/01/05	00961	T0281AUY		Pending	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design	2005/10/20	366.382	And the second s		
T0281AZA         South Africa         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/14           T0281AZA2         South Africa         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/14           T0281B         United States         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/05           T0284A         United States         Pending         MOIST LIPS         2006/01/05           T0285A         United States         Pending         MUTRIENT FACE FORTIFIER         2006/01/05	00961	T0281AWO	-	Pending	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design	2005/10/18	IR			TO SECURE A
T0281AZA2         South Africa         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/14           T0281B         United States         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/05           T0284A         United States         Pending         MOIST LIPS         2006/01/05           T0285A         United States         Pending         NUTRIENT FACE FORTIFIER         2006/01/05	00961	T0281AZA	South Africa	Pending	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design	2005/10/14	2005/22061			
T0281B         United States         Pending         N.V. PERRICONE, M.D. MEN'S         2005/10/05           SKIN FITNESS and Design         SKIN FITNESS and Design         2006/01/05           T0284A         United States         Pending         MOIST LIPS         2006/01/05           T0285A         United States         Pending         NUTRIENT FACE FORTIFIER         2006/01/05	00961	T0281AZA2	South Africa	Pending	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design	2005/10/14	2005/22062			
T0284A United States Pending MOIST LIPS 2006/01/05 T0285A United States Pending NUTRIENT FACE FORTIFIER 2006/01/05	19600	T0281B	United States	Pending	N.V. PERRICONE, M.D. MEN'S SKIN FITNESS and Design	2005/10/05	78/727,233			none na en . A consul significa page / s
T0285A United States Pending NUTRIENT FACE FORTIFIER 2006/01/05	00961	T0284A		Pending	MOIST LIPS	2006/01/05	78/785,748			
	19600	T0285A		Pending	Nutrient face fortifier	2006/01/05	78/785,784			Market Representation and the second

St. Onge Steward Johnston Reens LLC

Exhibit 4.12(d)

Run Date: 3/3/2006 11:51 AM

S Z	holas V	Nicholas V. Perricone Trademarks	radem	larks				- The state of the	
OPEN Ma	tters; CLIENTS:	OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*;	dusive t*;	The same of the same state of			MANAGEMENT ( ) () () () () () () () () () () () ()	To be a series of the first between the property and the series and the series of the	
CLIENT	MATTER	PROF. I LA LABORA DE LES CONTROVENISMENTO DE PROFESIONADO ADMINISTRAÇÃO DE LA CONTROVENISMENTO DE PROFESIONADO ADMINISTRAÇÃO DE LA CONTROVENISMENTO DE PROFESIONADO ADMINISTRAÇÃO DE LA CONTROVENISMENTO DEL CONTROVENISMENTO DE LA CONTROVENISMENTO DEL CONTROVENISMENTO DE LA CONTROVENISMENTO DEL CONTROVENISMENTO DE LA CONTROVENISMENTO DE LA CONTROVENISMENTO DEL CONTROVENISMENTO DE LA CONTROVENISMENTE LA CONTROVENISMENTO DE LA CONTROVENISMENTE LA CONTROVENISMENTE LA CONTROVENISMENTE	The state of the s	CONTRACTOR	FLKG		ISSUE		EXPIRE
00961	00961 T0286A	United Stated	Pending	BODY HYDRATOR	/05	<b>SEKIAL NO</b> 78/785,800	DATE	REG NO	DATE
00961	T0287A	United States	Pending	FACE HYDRATOR	2006/01/05	78/785,816			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
00961	T0288A	United States	Pending	HYDRATING NUTRIENT MASK	2006/01/05	78/785,824	* * * * * * * * * * * * * * * * * * *		
00961	T0289A	United States	Pending	GENTLE CLEANSER	2006/01/05	78/785,714			
00961	T0290A	United States	Pending	THE PERRICONE WEIGHT-LOSS DIET	2006/01/26	78/799,773	to e mentro i tanduccione de presi utimo que i tir el		
00961	T0291A	United States	Pending	DR. PERRICONE'S SKIN AND TOTAL BODY NUTRITIONAL SUPPLEMENTS	2006/01/26	78/799,785			
00961	T0291AKR	Korea	Pending	DR. PERRICONE'S SKIN AND TOTAL BODY NUTRITIONAL SUPPLEMENTS	2006/01/26	2006-4459			
00961		United States	Pending	N.V. PERRICONE, M.D., PHARMACEUTICALS	2003/03/26	78/305,861			
00961		United States	Pending	N.V. PERRICONE, M.D., PHARMACEUTICALS	2003/12/16	78/341,309	OR OR OTHER DESIGNATION OF THE PROPERTY OF THE		
> Z	. Perri	N.V. Perricone, M.D., Limited Trademarks	mited	Trademarks			Yes		
00961	T0248AGB	Great Britain	Registered	Registered COSMECEUTICAL	1996/06/15	2102840	1996/06/15	2102840	2006/06/15
-									

4.12(d)	
Exhibit	

Run Date: 3/3/2006 11:51 AM

Page 23 of 23 Pages

Z	holas \	Nicholas V. Perricone Trade	radem	marks	makanaran unu a				
OPEN M.	atters; CLIENTS:	OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*,	ndusive t*;	NPW ( PROC. MACCONC. CA. C.	100 miles 100 mi	Authorization (Company) (C		VP - 11 at a service of the transfer of the tr	** • PT TERRORETHINOCOLONOMOMOMOMOMOM mail force (F) or
		hallemanne (111 fr.) pr. (2); carlettanbiana na norma contrat (2) pr.) cardina tibro na samanda.  1 (117 fr.) de trassamanne (projektoristaklara p. 2 (11) voman samanjapisajektoristakna namandala.		THE THE PROPERTY COMMENTS AND THE PROPERTY OF	FILING		Tecile	mi r je o nakondopo o spore ( jehomo vskostojskemio izmatoko danakita za 1 rako m	restance
	CLIENT MATTER	COUNTRY	STATUS	Para	DATE	SFRIA! NO	DATE		בארואם
19600	T0279A	United States	Pending	N.V. PERRICONE, M.D. MEN'S FITNESS and Design	2005/08/26	78/701,367			
* has to the physiological distributions and the second se	1 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1					· · · · · · · · · · · · · · · · · · ·			
E E	demar	Trademarks filed by Brazilian Distributor	azilian	Distributor					As a source of the source of t
00961	00961 T0280ABR	Brazil	Published	DR. NICHOLAS PERRICONE and Design	2005/06/15	827475055	O MET TOTAL OF THE PRESIDENCE AND ADMINISTRATION OF THE PRESIDENCE	· V Andrewstein and resident and an area of the first transfer and area of the first transfer and an area of the first transfer and area of the fi	
00961	T0280BBR	Brazil	Published	DR. NICHOLAS PERRICONE and 2005/06/15 Design	2005/06/15	827475063			* * · * · · · · · · · · · · · · · · · ·
>. Z	'. Perri	N.V. Perricone, M.D., Limite	mited	d Tradenames N.V. PERRICONE, M.D. COSMECEUTICALS					

Page 1 of 6 Pages

Run Date: 3/2/2006 5:20 PM

CLIENT MATTER C 00961 T0063ACE U 00961 T0063ACZ C 00961 T0063AEG E 00961 T0063AEG E	COUNTRY Inited Arah Emit		•	-				
T0063AGE T0063ACO T0063ACZ T0063AGG	<b>SOUNTRY</b> Inited Arah Emit	Part 1 of Physiologyman man arrays are a planta as to see		FILING	(Aprile) and the anticle of a FA handed desirable subserve on democracy measure a single property.	TSSIIE		FXDIDE
T0063AAE T0063ACZ T0063AEG T0063AEG	Inited Arah Emit	STATUS			SERIAL NO	DATE	REG NO	DATE
T0063ACZ T0063AEG T0063AEG		United Arab Emit To Be Filed	N.V. PERRICONE, M.D. COSMECEUTICALS	2				
T0063AEG T0063AEG	Colombia	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/01/ 0	06-11.070			
T0063AEG T0063AGR	Czech Republic	To Be Filed	To Be Filed N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02		And the state of t		
T0063AGR	Egypt	To Be Filed	To Be Filed N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02		THE TO A PASSAGE PARTY AND A PASSAGE P	ACT OF A COLOR OF A CO	
1	Greece	To Be Filed	To Be Filed N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02				
AL COORTINATION OF THE COO	Hong Kong	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/01/26 300572643	00572643			
00961 T0063AIL IS	Israel	To Be Filed	To Be Filed N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02				
00961 T0063AJO JC	Jordan	To Be Filed	To Be Filed N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02				
00961 T0063AKW K	Kuwait	To Be Filed	To Be Filed N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02				
00961 T0063AMX1 Mexico	лехісо 1	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2005/03/03 705314	05314			

Run Date: 3/2/2006 5:20 PM

Page 2 of 6 Pages

コカ	plem	ental Ex	hibit 4	Supplemental Exhibit 4 12 (d) to APA					
OPEN Ma	ters, CLIENT	S: Inclusive 0096	1; MATTERS:	Inclusive t*;	The state of the s	*Communication of the state of	THE STATE OF THE S	To provide the property of the	
TENT	ZYLED				FILING	And the second s	ISSUE	SHE A. I. I AND SHE SOUTH SOUTH SHE SHE SHE SHE SHE SHE SHE SHE SHE SH	EXPIRE
	TOOCH	<b>K1</b>		decident Distinguists on the spaces to appropriate \$4.500 to \$1.500 to \$1.50		SERIAL NO	DATE	REG NO	
10600	I UU63AMXZ MEXICO		Registered	N.V. PERRICONE, M.D. COSMECEUTICALS	/03	705,398	2005/12/12 913,295	913,295	2015/03/03
00961	T0063APL	Poland	To File	N.V. PERRICONE, M.D. COSMECEUTICALS	20006/02/			der et des es communications de l'access d	
00961	T0063ARO	Romania	To Be Filed N.V.	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02	V. Commonwealth and the second			
00961	T0063ARU	Russia	Pending	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02/13	A margamentalism manadam a regular a salahan manadam a salahan manadam a salahan manadam a salahan manadam a s			
00961	T0063ASA	Saudi Arabia	To Be Filed	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02	ATTO 1 (A) CONTRACT AND LOCAL DESIGNATION OF THE PROPERTY OF T		To a first of the contract of	
00961	T0063ATR	Turkey	To Be Filed	N.V. PERRICONE, M.D. COSMECEUTICALS	2006/02			entrollindrande en	
00961	T0063C	United States	Pending	N.V. PERRICONE, M.D.	2006/01/26 78/799,850	78/799,850			
00961	T0063CAR	Argentina	To Be Filed	N.V. PERRICONE, M.D.	2009/02				
19600	Т0063СВМ	Bermuda	To Be Filed	N.V. PERRICONE, M.D.	2006/02				
00961	T0063CBR1 Brazil	Brazil	To Be Filed	N.V. PERRICONE, M.D.	2009/03	ve i ve forgen i mansk ve ekste minne se mansk major indrigitation interessione.			

St. Onge Steward Johnston Reens LLC

Run Date: 3/2/2006 5:20 PM

Page 3 of 6 Pages

	EXPIRE	DATE										
	THE COMMENT OF STREET, BUT THE COMMENT OF THE COMENT OF THE COMMENT OF THE COMMEN	REG NO	Addination of the state of the	Company and the same and the sa		a o de						
	ISSUE	DATE						To the state of th				
	ere ve e ette e e. j. j. habitat e e e e e e e e e e e e e e e e e e	SERIAL NO			Property of the control of the contr		**************************************		**************************************	Action to the control of the control	TO	
	FLING		2006/02	2006/02	2006/02		2006/02/06	2006/02	2006/02	2006/02	2006/02	2006/02
Supplemental Exhibit 4 12 (d) to APA OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*;	NA AARABANIN MARAKA MARAKA MARAKA MARAKA 1865 - 1875 - 1875 - 1875 - 1875 - 1876 - 1876 - 1876 - 1876 - 1876 - NA AARABA MARAKA MARAKA MARAKA MARAKA 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 - 1876 -	NAME	N.V. PERRICONE, M.D.	N.V. PERRICONE, M.D.	N.V. PERRICONE, M.D.	N.V. PERRICONE, M.D.	N.V. PERRICONE, M.D.	I.V. PERRICONE, M.D.	N.V. PERRICONE, M.D.	N.V. PERRICONE, M.D.	N.V. PERRICONE, M.D.	I.V. PERRICONE, M.D.
hibit 4		STATUS	To Be Filed N	To Be Filed	To Be Filed N	To Be Filed	Pending	To Be Filed N.V.	To Be Filed N	To Be Filed N	To Be Filed N	To Be Filed N.V.
Supplemental Exhibit 4 OPEN Matters, CLIENTS: Inclusive 00961; MATTERS: Inc	en dados a blombala en elektronista esta en el en espejo pajajajaja deplanataria. En el 10 de entre en transcontantaria entre en en en el en el en en en entre ent		Brazil	Bahamas	Canada	Chile	IR/China	Colombia	Costa Rica	Indonesia	India	Mexico
pleme		MALIEK COUNIKY	T0063CBR2	T0063CBS	T0063CCA	T0063CCL	T0063CCN	T0063CCO	T0063CCR	T0063CID	T0063CIN	T0063CMX1 Mexico
Sup OPEN Ma	-	-	00961	00961	00961	00961	00961	00961	00961	00961	00961	00961

St. Onge Steward Johnston Reens LLC

Run Date: 3/2/2006 5:20 PM

Page 4 of 6 Pages

35	plemo	Supplemental Exhibit 4		4 12 (d) to APA					
OPEN M.	itters; CLIENT	OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t	1; MATTERS:	Inclusive t*;		and the first control of the control	THE T. T. I. THE S. COMPLEMENTAL BROWNING AS A STATE OF	TARAFA DA PARAMANTAN ANTANTAN	
CLIENT	MATTER	COUNTRY	STATUS		FILING		ISSUE	Fried the manufacture with the miles of the state of the	EXPIRE
00961	T0063CMX2 Mexico	- Principal data Bases of the Conference of the	To Be Filed	N.V. PERRICONE, M.D.		SEKIAL NO		REG NO	DATE
00961	T0063CPA	Panama	To Be Filed	N.V. PERRICONE, M.D.	2006/02				1 m 1 m 1 m 1 m 1 m 1 m 1 m 1 m 1 m 1 m
00961	T0063CPE	Peru	To Be Filed N.V.	PERRICONE, M.D.	2006/02				
00961	Т0063СРН	Philipines	To Be Filed	N.V. PERRICONE, M.D.	2006/02				
00961	T0063CUY	Uruguay	To Be Filed	N.V. PERRICONE, M.D.	2006/02				
00961	T0063CVE	Venezuela	To Be Filed	N.V. PERRICONE, M.D.	2006/02				
00961	T0063CWO	International Registration	Pending	N.V. PERRICONE, M.D.	2006/02/06	ACTION AND A STATE OF THE STATE			The companies who described the companies when the
00961	T0273ABR	Brasil	Published	NEUROPEPTIDE FACIAL CONTOUR	2005/11/04 827916450	27916450			AND CONTRACTOR OF THE PARTY OF
00961	Т0273АСН	Switzerland	Registered	NEUROPEPTIDE FACIAL CONTOUR	2005/11/22 59728/2005	9728/2005	2005/11/25 542.269	542.269	2015/11/25
00961	T0273ASE	Sweden	Pending	NEUROPEPTIDE FACIAL CONTOUR	2005/11/01 2005/08186	005/08186			

St. Onge Steward Johnston Reens LLC

Run Date: 3/2/2006 5:20 PM

Page 5 of 6 Pages

	CVSTO	DATE							And the second s	The state of the s		
	TO THE COMMISSION AND AND ADDRESS AND ADDRESS AND THE POST OF THE					A. C. V. W. P. C. V. C. V. W. P. C. V. V. V. W. P. V. V. V. V. W. P. V. V. V. W. P. V.	The state of the s		AAA AAAA AAAA AAAA AAAA AAAA AAAA AAAA AAAA			
	11551	DATE			And 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1							
e et etter julija destruitionismus ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) (	To the transmission remains the second of the second of the second of the second secon	SERIAL NO	8/785,748	8/785,784	8/785,800	8/785,816	8/785,824	3/785,714	8/799,773	3/799,785	006-4459	3/305,861
		DATES	/05	2006/01/05 78/785,784	2006/01/05 78/785,800	2006/01/05 78/785,816	2006/01/05 78/785,824	2006/01/05 78/785,714	2006/01/26 78/799,773	2006/01/26 78/799,785	2006/01/26 2006-4459	2003/03/26 78/305,861
Suppliemental EXPIDIT 4 L2 (q) to APA OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive t*;	man and a transfer of the control of	A SA	MOIST LIPS	NUTRIENT FACE FORTIFIER	BODY HYDRATOR	FACE HYDRATOR	HYDRATING NUTRIENT MASK	GENTLE CLEANSER	THE PERRICONE WEIGHT-LOSS DIET	DR. PERRICONE'S SKIN AND TOTAL BODY NUTRITIONAL SUPPLEMENTS	DR. PERRICONE'S SKIN AND TOTAL BODY NUTRITIONAL SUPPLEMENTS	N.V. PERRICONE, M.D., PHARMACEUTICALS
IIIDIC 4 I; MATTERS:		2 11 017 000	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending
3: Inclusive 0096;	Sen milder Fresh v. 2004. Ten ver a st. east state on a summana despelação politorio perceptivo de distribuição	210000	United States	United States	United Stated	United States	United States	United States	United States	United States	Korea	United States
ters, CLIENTS	Market William Co.		T0284A	T0285A	T0286A	T0287A	T0288A	T0289A	T0290A	T0291A	T0291AKR	
OPEN Mat			00961	00961	. 19600	. 19600	00961	00961	. 19600	. 19600	00961	00961

St. Onge Steward Johnston Reens LLC

Page 6 of 6 Pages

Run Date: 3/2/2006 5:20 PM

Supplemental Exhibit 4 12	ental Ex	chibit,	<b>4 12 (d) to APA</b>	4		demonstrativa de de la		
OPEN Matters; CLIENTS: Inclusive 00961; MATTERS: Inclusive -	TS: Inclusive 009(	61; MATTERS:	Inclusive t*;		, the control that and processes and processes of the control of t	random rate out out or or		
				FILING			ACO II MARA I INM MOTO A MORRO II - III ANVAMBANTI MARAKATA (Andream dau dake un persona da companya da company	
CLIENT MATTER	COUNTRY	STATUS	NAME	DATE	SERIAL NO	DATE	REG NO	DATE
00961	United States	Pending		2003/12/16	78/341,309			THE CONTRACTOR STREET STATE OF THE CONTRACTOR STATE OF TH

# SCHEDULE C

# LOCATIONS OF EQUIPMENT AND INVENTORY

Location	Qualified to do business in such location?	Description of Equipment / Inventory Held with 3 <sup>rd</sup> Parties	Approximate Value of Equipment/Inventory Held with 3 <sup>rd</sup> Parties
639 Research Parkway (1 <sup>st</sup> and 3 <sup>rd</sup> Floors), Meriden, CT 06450-7154 <u>Lessor</u> : Mediterranean Realty, LLC	Yes	N/A	
791 Madison Avenue, New York, NY 10021-6106 Lessor: Lawrence Friedland and Melvin Friedland c/o Larstrand Corporation	Yes	N/A	
109 Sanford Street, Hamden, CT 06514 Third Party: Fulfillment Works, LLC	Yes	Products*	
2600 Titan Row, Orlando, FL 32809 Third Party: Southland Logistics	Yes	Products*	
Studio Park, 1200 Wilson Drive, West Chester, PA 19380 Consignee: QVC, Inc.	No	Products*	
2323 South West Temple, Salt Lake City, UT 84115 Manufacturer: Sorenco	No	Products Components (e.g., chemicals and Product ingredients)	
RR1, Clinton, IL 61727 <u>Manufacturer</u> : HNC	No	Products Components (e.g., chemicals and Product ingredients)	

Security Agreement CLI-1356691

1764 Litchfield Tpke, Woodbridge, CT 06525 <u>Manufacturer</u> : S. Gould	Yes	Products Components (e.g., chemicals and Product ingredients)
260 Branford Road, North Branford, CT 06471 <u>Manufacturer</u> : Brook and Whittle	Yes	Products Components (e.g., chemicals and Product ingredients)
44 Berkshire Road, Sandy Hook, CT 06482 <u>Manufacturer</u> : Curtis Packaging Corporation	Yes	Products Components (e.g., chemicals and Product ingredients)
1540 NW 94 Ave., Miami, FL 33172  Manufacturer: Sothy	Yes	Products Components (e.g., chemicals and Product ingredients)
8 Henderson Drive, West Caldwell, NJ 07006 <u>Manufacturer</u> : Garden State Nutritional	No	Products Components (e.g., chemicals and Product ingredients)
10 Marshall Street, Wallingford, CT 06492  Manufacturer: Matthews  Printing	Yes	Products Components (e.g., chemicals and Product ingredients)
34 Campground Road, Old Mystic, CT 06372 Processor: Carwild Corp.	Yes	Stimulation Glove Mold

<sup>\*&</sup>quot;Products" means all goods and other property including all skincare products, including, without limitation, cleansers, toners, eye creams, serums moisturizes, body and hand creams manufactured, developed or sold.

CLI-1356691v4

# SCHEDULE D

## **LOCATIONS OF BOOKS AND RECORDS**

# 1. <u>Chief Executive Office</u>

639 Research Parkway (1<sup>st</sup> and 3<sup>rd</sup> Floors), Meriden, CT 06450-7154

# 2. Locations of Account Records and Chattel Paper

639 Research Parkway (1<sup>st</sup> and 3<sup>rd</sup> Floors), Meriden, CT 06450-7154

Security Agreement CLI-1356691

#### SCHEDULE E

## DEPOSIT ACCOUNTS, CERTAIN INVESTMENT PROPERTY AND LETTERS OF CREDIT

	1.	. ]	Deposit Accounts
--	----	-----	------------------

Name and Address of Institution Holding Account

Account Nos.

2. Securities Accounts and Other Investment Property

None

3. Letters of Credit Issued for the Benefit of the Grantor

None

Security Agreement CLI-1356691

# SCHEDULE F

# UCC FILING OFFICES AND STATE ORGANIZATIONAL IDENTIFICATION NUMBER

Filing Office State Organizational Identification Number

Delaware Secretary of State 4061869

Security Agreement CLI-1356691

#### FORM OF LIMITED LIABILITY COMPANY NOTICE

TO: [Name of Pledged Entity]

Notice is hereby given that, pursuant to the Security Agreement dated as of March 3, 2006 (said Agreement, as it may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"), made by N.V. Perricone LLC (the "Grantor"), in favor of Union Bank of California, N.A., as Agent (the "Agent") on behalf of the Secured Party described therein, the Grantor has pledged and assigned to the Agent for the ratable benefit of the Secured Party, and granted to the Agent for the ratable benefit of the Secured Party, a continuing security interest in, all right, title and interest of the Grantor, whether now existing or hereafter arising or acquired, as a member in [NAME OF PLEDGED ENTITY] (the "Limited Liability Company"), and in, to and under the [TITLE OF APPLICABLE LIMITED LIABILITY COMPANY AGREEMENT] (said Agreement, as it may be amended, restated, supplemented or otherwise modified from time to time, the "Limited Liability Company Agreement"), as such security interest is more particularly described in the Security Agreement.

Pursuant to the Security Agreement, the Limited Liability Company is hereby authorized and directed to register the Grantor's pledge to the Agent on behalf of the Secured Party of the interest of the Grantor on the Limited Liability Company's books.

The Grantor hereby requests the Limited Liability Company to indicate the Limited Liability Company's acceptance of this Notice and consent to and confirmation of its terms and provisions by signing a copy hereof where indicated on the attached page and returning the same to the Agent on behalf of the Secured Party.

N.V. PERRICONE LLC

By:	
Name:	
Title:	

#### FORM OF ACKNOWLEDGMENT

[NAME OF PLEDGED ENTITY] (the "Limited Liability Company") hereby acknowledges receipt of a copy of the assignment by N.V. PERRICONE LLC (the "Grantor") of its interest under the [TITLE OF APPLICABLE LIMITED LIABILITY COMPANY AGREEMENT] (as it may be amended, restated, supplemented or otherwise modified from time to time) pursuant to the terms of the Security Agreement dated as of March 3, 2006 (as it may be amended, restated, supplemented or otherwise modified from time to time in accordance with the terms thereof), made by the Grantor in favor of Union Bank of California, N.A., as Agent (the "Agent") on behalf of the Secured Party described therein. The undersigned hereby further confirms the registration of the Grantor's pledge of its interest to the Agent on behalf of the Secured Party on the Limited Liability Company's book. The undersigned acknowledges the control by the Agent of the Grantor's interest in the Limited Liability Company and confirms that the undersigned shall upon the occurrence and during the continuance of an Event of Default comply with instructions originated by the Agent with respect to such interest without the further consent by the Grantor

consent by the Grantor.	
Dated:,	
	[NAME OF PLEDGED ENTITY]
	By:
	Name:
	Title:

Security Agreement

TRADEMARK REEL: 003259 FRAME: 0575

RECORDED: 03/06/2006